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ABSTRACT

TRANSCRIPTOMICS AND TOXCAST DATA IDENTIFY BIOEFFECTS IN
ZEBRAFISH EMBRYOS EXPOSED TO CHEMICAL MIXTURES IN AN
EFFLUENT-DOMINATED STREAM
by
Emma Bramfeld Meade
The University of Wisconsin-Milwaukee, 2021
Under the Supervision of Professor Rebecca Klaper

Wastewater treatment plant (WWTP) effluent-dominated streams provide critical
habitat for aquatic organisms but also continually expose them to complex mixtures of
pharmaceuticals and other contaminants of emerging concern (CECs) that can potentially
impair growth, behavior, and reproduction. Limited toxicity data on the adverse biological
impacts of in vivo exposure to these mixtures make it difficult to assess risk for aquatic
organisms, particularly with respect to pharmaceuticals whose designed bioactivity often
extends beyond conventionally monitored biological pathways. To address this knowledge gap,
the goal of this thesis was to identify biomarkers of exposure to complex CEC mixtures relevant
to specific chemicals and mixtures in an effluent-dominated stream. RNA sequencing and
targeted gene expression were used to identify novel gene and pathway-based impacts of
exposure to complex mixtures of pharmaceuticals and other CECs as they related to
developmental stage in zebrafish (Danio rerio) larvae and seasonal changes in the chemical
ii

mixture composition of the stream. High throughput screening data from the ToxCast database
were used to predict biological impacts based on measured chemical concentrations. Together,
these data suggest several associations between chemicals (diphenhydramine and
thiabendazole) and impacts observed in zebrafish exposures (histaminergic and cardiovascular).
While some pathway-based impacts observed in zebrafish exposures were also predicted by
ToxCast, many were not (e.g., visual system, musculoskeletal, and metabolic). The results of this
work demonstrate a need to expand the ToxCast assay library to encompass bioeffects specific
to fish and relevant to pharmaceutical mixtures in WWTP effluent.
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Chapter 1: Introduction
Contaminants of emerging concern (CECs), which include pharmaceuticals, food
additives, flame-retardants, and plasticizers, are largely unregulated but have potential to enter
the environment and cause adverse biological effects at environmentally relevant
concentrations. Like many emerging contaminants, pharmaceuticals have poorly understood
ecotoxicological impacts and are detected globally in surface water,1–5 groundwater,6,7 and
wastewater treatment plant (WWTP) effluent and influent.8,9 The occurrence of
pharmaceuticals in surface water is of particular concern with respect to aquatic species for
several key reasons: (1) their designed bioactivity can effect off-target species,10 (2) sublethal
impacts, which can be consequential to population health but difficult to measure, include
altered behavior, reproductive success, and disease resilience, and (3) complex mixtures can
result in synergistic toxicities and other interactive effects.11–13 Ability to detect environmental
contaminants at very low concentrations (ng-µg/L) has vastly outpaced ability to interpret their
biological significance,14 and ecotoxicological data relevant to aquatic organisms is not available
for most pharmaceuticals.15 Thus, the task of characterizing potential effects and risks of
adverse outcomes that stem from exposure to pharmaceutical residues in aquatic
environments is enormously complex.
The primary route of entry into the environment for pharmaceuticals is through WWTP
effluent discharged into surface water,16 often small, lower-order streams.1 Conventional
wastewater treatment processes, which achieve removal of biodegradable organic matter
through adsorption to activated sludge and microbial breakdown, are not designed to remove
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pharmaceuticals. Pharmaceuticals tend not be metabolized by microbes17 and may not sorb to
solids during filtration due to hydrophilicity,18 thus removal efficiencies in conventional facilities
can be quite low.8,19,20 Pharmaceuticals encompass compounds with an enormous range of
chemical and physical properties, but for many their resistance to degradation is by design. The
stability of pharmaceuticals within the body often allows for greater efficiency and specificity in
reaching the therapeutic target. For example, the addition of a fluoro-group, which increases
the potency and bioavailability of a drug, is common in many highly used pharmaceuticals
known to be persistent in the environment including antibiotics (ciprofloxacin) and
antidepressants (fluoxetine, citalopram).21 Although most pharmaceuticals tend not to be
highly persistent, continuous input from WWTP effluent can create chronic exposure conditions
for aquatic organisms,22 particularly in small streams where minimal dilution occurs. Consistent
detections of pharmaceuticals in remote streams further illustrate the persistence and mobility
of many CECs in surface water23,24 and make it imperative to characterize the biological risks of
exposure in effected aquatic ecosystems.
In addition to poor removal efficiencies, widespread detections of pharmaceuticals in
surface water can also be attributed to increased consumption25 and population growth in
areas where effluent release occurs away from major rivers and tributaries with high dilution
capacity.26,27 Pharmaceutical consumption has been on the rise globally for the past several
decades with 39% growth in antibiotic usage between 2000 and 2015.28 While most of the
recent growth is driven by countries in South America, Asia, and Africa,29 the United States
retains its place near the top in per capita consumption of pharmaceuticals. Nearly half of U.S.
Americans reported taking one or more prescription drugs in the past 30 days in a 2007-2010
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survey with 10% taking 5 or more prescribed drugs.30 In 2011-2014, 12.7% of the US population
aged 12 and over reported use of antidepressants in the past month.25 Population growth and
the urbanization of watersheds also contributes to the dispersal of pharmaceuticals in surface
water, particularly in arid and semi-arid regions without major river systems and stressed
groundwater reserves. In these areas, WWTP effluent release is likely to dominate receiving
waters which provide the critical ecosystem service of maintaining aquatic and riparian habitat
and also supply drinking water intakes.26
Aquatic species have often served as sentinels of pollution that can impact human
populations, and another motivation for characterizing the sublethal impacts of wastewater
exposure is the occurrence of pharmaceuticals and CECs in treated drinking water. Like
conventional WWTPs, conventional drinking water treatment plants (DWTPs) provide
insufficient removal of pharmaceuticals. Although advanced secondary treatments that use
granular activated carbon and membrane filtration can improve removal efficiencies,31 the
separation of wastewater effluent release from DWTP intakes provides the most protection. It
is estimated that more than 50% of DWTPs serving populations of 10,000 or more are
positioned downstream of at least one WWTP discharge,32 which presents the possibility of
wastewater CECs emerging in finished drinking water.33 In effluent-dominated streams, the
volume of WWTP effluent tends to be consistent regardless of the baseflow in the receiving
stream, so drought has the effect of increasing the effluent portion of streamflow. In decreased
streamflow conditions projected by climate change models, the median effluent portion of
water entering drinking water intakes positioned downstream of WWTPs in the US would rise
from 3.6% (current) to 46%.32 While impact of CECs on watersheds receiving WWTP effluent is
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likely to become more pronounced with climate change throughout the arid and temperate
U.S,32 disparities in the impact of de facto wastewater reuse are already evident. In Texas, small
communities (pop. < 3300) are both more likely to experience high de facto reuse of
wastewater (greater than 20%) and less likely to have DWTPs with advanced treatment
capability.34 Without national health-based water quality standards for pharmaceuticals and
CECs, pharmaceutical levels in drinking water and surface water remain unregulated. The
increasing de facto reuse of WWTP effluent should inspire serious investment in understanding
and managing the potential public health consequences of CEC persistence in surface
freshwater. In many parts of the US, water shortages make de facto reuse of WWTP effluent
inevitable.35
Over 900 streams across the U.S. are composed of at least 50% effluent.32 These
effluent-dominated streams provide important habitat for aquatic organisms but continually
expose them to complex mixtures pharmaceuticals and CECs. The concentrations at which
pharmaceuticals and other CECs are typically found in the surface water are such that acute
toxicity is rare, yet many studies have shown that chronic low level exposures in aquatic
organisms can alter endocrine system functioning and result diminished reproductive success,
changes in offspring sex ratios, and impaired reproductive behavior.36–38 A dramatic example of
endocrine disruption in wild fish populations across the US the widespread occurrence of
testicular oocytes in males, which has been associated with exposure to WWTP effluent and
other non-point pollution sources such as agricultural run-off and human waste input from
septic tank failures.39,40
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Endocrine disruption effects in fish are well documented among pharmaceuticals across
many drug classes, including neuro-pharmaceuticals, antibiotics, and diabetes medications.41
Initially, the study of endocrine disruption in xenobiotics emphasized the structural similarity of
a compound to estrogen or other endogenous hormones to establish potential for interference
with hormone receptor binding.42 Compounds with estrogen-like ring structures such as
bisphenol-A (BPA) and phthalates are examples. However, endocrine system responses to
xenobiotic exposures are not based solely on interference with hormone receptors, but rather
may result from many interconnected biological pathways as is the case with many
pharmaceuticals.
The ecotoxicological effects of antidepressants and other neuro-pharmaceuticals on
neuroendocrine signaling pathways has received a great deal of attention in the past two
decades.43 Neurotransmitters modulated by antidepressants in the selective serotonin reuptake
inhibitor (SSRI) class, for example, are responsible for the stimulation of reproductive hormone
pathways. Increased serotonin levels that result from SSRI inhibition of serotonin reuptake may
inappropriately activate the hypothalamus-pituitary-gonadal (HPG) axis in fish.44,45 Amplified
stimulation of the HPG axis is likely a factor in the over expression of estrogen-responsive
genes, including the egg yolk protein vitellogenin, which has been observed in fish exposed
environmentally relevant concentrations of fluoxetine (0.028 μg/L).46 At a slightly higher
environmentally relevant concentration of 1 μg/L, fluoxetine alters behaviors important for
successful reproduction in fish including nest-building in fathead minnows (Promelas
pimephales),47 and social interactions in medaka (Orzyzias latipes).48
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Metformin, prescribed for management of diabetes and polycystic ovarian syndrome,
also impacts reproductive functioning through a variety of interconnected pathways.
Metformin acts as an insulin sensitizer through activation of the AMP kinase (AMPK) pathway
and bears no structural resemblance to estrogen.49 Yet, it has also been linked to adverse
reproductive impacts in fish including reduced fecundity and induction of testicular oocytes in
males.50–52 These endocrine disruption responses highlight the interconnected nature of the
metabolic, neurological, and hormonal pathways that impact behavior and physiology.
Reproductive impairments can be devastating to wild fish populations53 and the
attention endocrine disruption has received in ecotoxicology of pharmaceuticals is warranted.
However, there are many more biological pathways relevant to pharmaceutical exposures in
fish that are poorly understood. Pharmaceuticals are often designed to target specific receptors
in humans that have close homologs in other species, including fish. Examples of
pharmaceuticals with protein targets (e.g., enzymes, receptors, and ion channels) that are
homologous in fish include antidepressants (serotonin receptors),54 beta-blockers (β-adrenergic
receptors),55–57 non-steroidal anti-inflammatory drugs (cyclooxygenase (COX) enzymes),58 and
cholesterol-lowering drugs (peroxisomal proliferator-activated receptors).59 Although the
protein targets of pharmaceuticals may be structurally similar across species, their specific
functions can vary. For example, cyclooxygenase enzymes, which synthesize prostaglandins
used to respond to injury and are homologous across many species, also has additional
functions like eggshell formation in birds.58
Beyond therapeutic design, many other factors also shape and mediate the biological
effects of pharmaceuticals on fish, particularly with respect to experience when exposed to
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pharmaceuticals, environmental samples containing pharmaceutical mixtures. These factors
include the duration, intensity, and developmental timing of an exposure; the interactive
effects of chemicals within a mixture and additional off-target mechanisms of action; the
mobility of chemicals across tissue types; and an individual’s compensatory response to
exposure. In real world exposure scenarios, the chemical composition of mixtures evolves
spatially over the reach of a receiving stream and seasonally with changing patterns of human
pharmaceutical use.1 While lab-based exposures to select chemicals are critical, field and labbased exposures using environmental samples capture more realistic exposure responses. The
use of ‘omics data, which identifies and quantifies the global the entirety of given biomolecule
(e.g., RNA, protein, metabolite) detected within a sample, provides a broad view of exposure
responses and allows for the identification of impacts across all mapped biological pathways.
Establishing transcriptomic signatures of exposure to chemical mixtures in effluent can identify
biological pathways with potential relevance to chemicals within mixtures.60,61 This approach to
identifying potential exposure impacts from complex pharmaceutical mixtures is taken in
Chapter 2 of this thesis.
Change across the transcriptome can help identify biologically meaningful responses in
chemical mixture exposures, and chemicals in single and multiple contaminant exposures can
be distinguished through barcode-like responses within the transcriptome.62 However, gene
expression alone does not yet provide the specificity needed to prioritize chemicals, mixtures,
and effects for further investigation.63 Few genes are specific to single biological functions and
many act widely across many different biological pathways. Another approach to interpreting
the potential risks of biological impacts from exposure to complex chemical mixtures involves

7

leveraging high throughput screening (HTS) in vitro assay data relating chemical concentrations
to biological effects as an interpretive lens. The Toxicity Forecaster (ToxCast) database from the
US EPA is one such tool.64 The database is comprised of hundreds of thousands of data points
representing dose-response curves for over 9,000 chemicals screened in highly standardized
biochemical and cell-based assays targeting a wide range of biomolecular and cell-based
functions. Because of the highly standardized nature of these assays, activity with respect to
specific biological targets can be compared across chemicals and across assay platforms. In
Chapter 3 of this thesis ToxCast assay data is used to predict the bioeffects of exposure to
pharmaceuticals and other CECs detected in an effluent-dominated stream. ToxCast assay data
has been used in this way to prioritize contaminants and mixtures for future study in a wide
range of contexts.65–67
The broad objective of this thesis was to identify the potential biological impacts of
exposure to complex pharmaceutical and CEC mixtures in Muddy Creek, an effluent-dominated
stream in Iowa, and to relate those impacts to spatial and seasonal changes in chemical
composition. The research presented in Chapter 2 profiles the transcriptome-level changes in
larval zebrafish at two developmental stages exposed to water samples taken above, at, and
below the WWTP effluent outfall in Muddy Creek during the months of January and May.
Transcriptome signatures unique to each month and developmental stage were identified, as
were genes with consistent expression patterns between months. Chapter 3 of this thesis uses
ToxCast assay data to predict bioeffects of exposure to chemical mixtures detected over seven
monthly sampling events along an effluent dominated stream. Predicted effects were
compared to the gene and pathway level effects identified in targeted and non-target gene
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expression from in vivo fish embryo exposures to environmental stream water samples of the
same months.
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Chapter 2: Zebrafish embryo exposure to effluentdominated stream water reveals transcriptome
signatures specific to developmental stage and seasonal
changes related to emerging contaminants
2.1

Introduction
Wastewater effluent containing complex mixtures of pharmaceuticals and other

contaminants of emerging concern (CECs) poses an increasing threat to environmental health,
and small effluent-dominated streams with minimal dilution are particularly at risk.
Conventional wastewater treatment plants (WWTPs) were not designed to remove these
chemicals, resulting in their frequent detection and wide distribution in surface water including
drinking water sources.23,24,68 Although effluent discharged into small streams typically
undergoes substantial dilution once released into higher order waterways, small receiving
streams provide important habitat in aquatic and riparian ecosystems.69 The continual presence
of bioactive chemical inputs can produce exposure conditions at concentrations with
documented harm to aquatic organisms,70 particularly during early life stages.71,72
Fundamental knowledge gaps still limit current understanding of how complex chemical
mixtures impact aquatic organisms. Substantial research has focused on interference with
steroidal reproductive hormones;41,73,74 however, pharmaceuticals have many targets and act
upon multiple biological pathways. Embryonic exposures can be particularly consequential and
can lead to physiological and behavioral impacts later in development75,76 and across
generations.77,78 Furthermore, pharmaceutical bioactivity often extends beyond the chemicallyengineered therapeutic design, causing sublethal impacts at low concentrations (ng/L-μg/L
10

range)79 that traditional toxicological endpoints are not designed to measure.73,80,81 For
example, the insulin-sensitizing diabetes drug, metformin, impairs growth in fish (1-3 μg/L)51,82
and can induce intersex condition in fathead minnow testes (40 μg/L).83 In many fish species,
environmentally relevant concentrations of antidepressants (less than 1 μg/L) are reported to
disrupt stress responses (venlafaxine),84 reproductive and predator avoidance behaviors
(fluoxetine),47 brain monoamine levels (venlafaxine),85 and diurnal activity patterns
(fluoxetine/sertraline/venlafaxine mixtures).86 Finally, the dynamic evolution of pharmaceutical
mixtures1 and complex interactive effects between chemicals87 are difficult to model in a lab,
and modulating factors like temperature88 and pH89,90 make field studies indispensable to the
task of characterizing the biological impacts of effluent exposure. Considering these challenges,
RNA sequencing is an appropriate and powerful tool for characterizing the biological effects of
effluent on aquatic organisms exposed to field and field-like conditions.
Larval zebrafish (Danio rerio) are an excellent model for identifying transcriptome-based
biological effects of effluent exposure. Because the zebrafish genome is fully sequenced and
biological pathways are largely conserved across vertebrates,91 identified impacts that are likely
relevant to other aquatic organisms as well. Tracking gene expression at multiple time points
during embryo and early larval development provides key insight as (1) development is a highly
coordinated process dependent upon completion of successive stages,92,93 and (2) stages differ
in vulnerability to environmental perturbations that disrupt development.94,95 Our research
objective was to relate the transcriptomic response of zebrafish embryos exposed to water
samples from an effluent-dominated stream to its evolving chemical composition as described
in Zhi et al. (2020).1 An additional goal was to identify biomarkers of effluent exposure that
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broaden the range of biological impacts that could be monitored in surface water containing
emerging contaminants from wastewater. Zebrafish embryos at 3 and 6 days post-fertilization
(dpf) were used to characterize the transcriptomic impacts of WWTP effluent across the
reaches of an effluent-dominated stream 100 meters above and below the effluent outfall.
These two developmental stages represent periods before and after reliance on yolk ends and
thus capture distinct vulnerabilities to environmental insult. Water samples used for exposures
in this study were taken in two seasons (winter and spring) and selected due to their
contrasting pharmaceutical profiles. We hypothesized that effluent exposure would reveal
biological effects beyond current endocrine system related biomarkers, that gene expression
would vary with chemical exposure over two seasons, and that disrupted biological pathways
would differ by stage of development.
2.2

Materials and Methods

2.2.1 Study Sites and Water Sampling
Muddy Creek is a small effluent-dominated stream in Coralville, Iowa (latitude
41°42ʹ00ʺ, longitude 91°33ʹ46ʺ) that receives approximately 5,300 m3 of effluent per day from
the North Liberty WWTP96 and discharges to the Iowa River. The stream’s 22.5 km2 drainage
area encompasses a mix of suburban (60%) and agricultural land uses (24.5%).1 Three
previously established USGS sampling sites were used: (1) 0.1 km above the WWTP outfall
(US1), (2) the effluent outfall (effluent), and (3) 0.1 km below the outfall (DS1) (Figures A.1 and
A.2). Monthly grab samples using the single vertical at centroid-of-flow method97 were taken in
triplicate from each site over 12 baseflow sampling events between September 2017 and
August 2018. Replicate samples were used for measurement of 113 pharmaceuticals using a
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previously published USGS method,98 a bioluminescent yeast estrogenicity assay,99 and
zebrafish embryo exposures.62 Water samples were shipped on ice to the University of
Wisconsin-Milwaukee where they were stored at -80ºC prior to use in zebrafish embryo assays
and to the USGS Organic Geochemistry Research Lab (Lawrence, KS) for solid phase
extraction100 prior to estrogenicity analysis at the Eastern Ecological Science Center
(Kearneysville, WV). Further characterization of the field sites, detailed methods for water
sampling, and analysis of the monthly chemical data are available in Zhi et al. (2020).1
2.2.2 Animals
Zebrafish embryos were obtained from group spawning events of a wild type 5D
zebrafish lab culture (University of Wisconsin-Milwaukee). Adult zebrafish of mixed sexes were
housed in a flow-through aquatic system (Aquaneering, San Diego, CA) with recirculating
dechlorinated municipal water and fed TetraMin flake twice daily. The system was maintained
at 27ºC in a 16:8-hr light/dark cycle. All procedures were conducted in accordance with animal
use and care protocols approved by the Institutional Animal Care and Use Committee of the
University of Wisconsin-Milwaukee.
2.2.3 Embryo exposures
Fertilized embryos were screened for uniformity in developmental stage progression.
Simultaneous 3- and 6-day exposures were performed separately using five replicate petri
dishes containing groups of 20 embryos (6 hours post-fertilization) immersed in 30 mL of
sample water from each site. Parafilm-sealed petri dishes were incubated at 27°C under a 16:8hour light/dark schedule. Upon completion, surviving larval fish from each replicate dish were
pooled into 1.5 mL tubes and snap frozen in liquid nitrogen for RNA extraction. Samples
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exposed to the January and May 2018 US1, effluent, and DS1 sites were selected for RNA
sequencing in this study. The selection of January and May sampling events was based on prior
published work1 at this site in which these months captured seasonal pharmaceutical use
patterns with higher concentrations of antibiotics in January and antihistamines in May (Figure
A.3). The site above the outfall (US1) was used as an in-stream baseline for assessing the
relative impact of wastewater effluent exposure.
2.2.4 RNA Sequencing
RNA Extraction, Library Prep, and Sequencing. Total RNA was isolated using standard
protocol for Direct-zol RNA MiniPrep (Zymo Research, R2051). Whole embryos were
homogenized in TRIzol with a pestle in a microfuge tube, and RNA was purified on Zymo-Spin
IIC columns. Sample purity was assessed with a NanoDrop spectrophotometer (Thermo Fisher
Scientific, Waltham, MA) with acceptable wavelength ratios of 1.8-2.0 for 260/280nm and 2.02.2 for 260/230 nm. RNA integrity (RIN) was measured on an Agilent Bioanalyzer 2100 (Agilent,
Santa Clara, CA), and samples with a RIN>7 were used. RNA was quantified on a Qubit 2.0
fluorometer (Invitrogen, Thermo Fisher Scientific, Waltham, MA). Two samples (January US1 3
dpf and May US1 6 dpf) had RIN scores below 7 and were not used for RNA sequencing.
Libraries were prepared using Illumina TruSeq Stranded mRNA sample preparation kit (Illumina,
RS-122-2102) and IDT for Illumina – TruSeq RNA UD Indexes (Illumina, 20022371) following
standard protocol, using 200ng of total RNA. Libraries were sequenced on an Illumina
NovaSeq6000 (paired-end 150 bp reads).
Processing of RNAseq Data. The total genomic yield surpassed 2.104 billion paired-end
reads with a median per-sample yield of 51 million fragments and a population standard
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deviation of 14 million fragments. Sequence data was quality-assessed using FastQC v0.11.5,101
and sequencing adapters were clipped using Cutadapt v1.18. The resulting quality-controlled
data was pseudoaligned and sample-quantified against the GRCz11 Ensembl release of the
zebrafish reference transcriptome using Kallisto v0.45.0.102,103
DaMiRseq was used to filter and normalize raw count data.104 Transcripts were removed
if they had fewer than 10 counts across 70% of samples or were hypervariant (coefficient of
variance threshold of 3). Raw counts were normalized to library size using variance stabilizing
transformation (vst), which reduces the dependence of the mean on variance. DESeq2 was used
to perform analysis of differential expression between the upstream baseline (US1) and the
effluent and DS1 samples.105 Resulting tables of differentially expressed transcripts (DETs) were
re-annotated with Ensembl reference information and relationally joined with Kallisto sample
quantification counts using custom tooling. Transcripts differentially expressed at the effluent
and DS1 sites (vs. US1) were considered significant at a Benjamini-Hochberg (B-H) adjusted pvalue<0.01 and |log2 fold change|>1. To characterize developmental differences at the
upstream reference site, DESeq2 was also used to perform analysis of differential expression
between the 3 and 6 dpf exposures to US1 samples from the same month. Transcripts were
considered to have significantly higher expression at 3 dpf (vs. 6 dpf) and 6 dpf (vs. 3 dpf) at a BH adjusted p-value<0.01 and |log2 fold change|>1. RNA-seq data are available in the National
Center for Biotechnology Information’s Gene Expression Omnibus under accession number
GSE179335.
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2.2.5 PLS-DA and Functional Enrichment.
MixOmics106 was used for partial least squares-discriminant analysis (PLS-DA) to
determine the relative influence of month, exposure length, and site on the overall
transcriptome. PLS-DA was performed over all exposures to compare the influence of month
and exposure length and performed separately over the 3 and 6 dpf exposures to compare the
influence of month and site.
Overrepresentation analysis was conducted on DETs from each comparison using the
Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway database107 and gene ontology
(GO) annotations from the Gene Ontology Consortium. GO terms and KEGG pathways
overrepresented among significant DETs (vs. US1) were identified using clusterProfiler108 which
employed hypergeometric enrichment tests with a B-H adjusted p-value<0.05 to control for
multiple testing and an FDR<0.1. GO terms and KEGG pathways overrepresented among
significant US1 3 dpf DETs (vs. 6 dpf) and 6 dpf DETs (vs. 3 dpf) were identified through
hypergeometric enrichment tests in g:Profiler using a custom g:SCS significance threshold to
control for multiple comparisons and a corrected p-value cutoff of 0.05.109
2.2.5 Bioluminescent Yeast Estrogenicity
Total estrogenicity of sample extracts100 was determined using the bioluminescent yeast
estrogen screen (BLYES) as previously described,99,110 but with minor modifications detailed in
Appendix A. The detection limit for this assay was 0.18 ng/L E2Eq(BLYES).
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2.3

Results and Discussion

2.3.1 Transcriptome profiles correspond to effluent chemistry differences across exposure
month and differ by developmental stage.
Signatures of WWTP effluent were present in both months at each developmental stage,
evident in the full transcriptome and in the proportion of DETs (vs. US1) shared between the
effluent and DS1 sites, whose similar chemical profiles are the result of the minimal dilution of
the effluent at DS1 (82% in both months).1 Developmental stage was a strong determinant of
the transcriptome profile among all samples (Figure 2.1a). Similarity between the effluent and
DS1 sites was evident in PLSDA performed separately on the 3 and 6 dpf exposures where the
effluent and DS1 sites of each month were more similar to each other than to the US1 site
(Figure 2.1b and c). The influence of effluent exposure was also evident in the proportion of
DETs shared between the effluent and DS1 sites within a month and developmental stage. In
the January 3 and 6 dpf exposures, 40-42% of DETs were shared between the effluent and DS1
sites. In the May exposures, 76-82% of DETs were shared between sites (Figure 2.1e). All DETs
shared between sites within the same month and developmental stage had consistent fold
change directions (positive or negative). The overlap between the effluent and DS1
transcriptomes likely reflects the high proportion of effluent to DS1 streamflow in both months:
89% in January and 80% in May (Table A2).111 Total concentrations of detected chemicals at the
effluent and DS1 sites were 15851 and 13013 ng/L in January and 16844 and 13743 ng/L in
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May, respectively (Figure A.3). Minimal dilution of the effluent (82% both months) was the only
identifiable source of attenuation at DS1.1

Figure 2.1. Partial least squares discriminant analysis (PLS-DA) of January and May samples exposed to water from
the effluent, DS1, and US1 sites at 3 dpf and 6 dpf. Ovals represent 95% confidence intervals. Sites: ＋ = US1, ⃤ =
effluent, and ⃝ = DS1. (A) PLS-DA using samples grouped by month of exposure and developmental stage: Jan 3
dpf (n=14), Jan 6 dpf (n=15), May 3 dpf, (n=15), May 6 dpf (n=14). (B) PLS-DA of 3 dpf samples classified by month
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and site: Jan 3 dpf US1 (n=4), Jan 3 dpf effluent (n=5), Jan 3 dpf DS1 (n=5), May 3 dpf US1 (n=5), May 3 dpf effluent
(n=5), May 3 dpf DS1 (n=5). (C) PLS-DA of 6 dpf samples classified by month and site: Jan 6 dpf US1 (n=5), Jan 6 dpf
effluent (n=5), Jan 6 dpf DS1 (n=5), May 6 dpf US1 (n=4), May 6 dpf effluent (n=5), May 6 dpf DS1 (n=5). (D) The
total number of upregulated (red) and downregulated (green) transcripts with significant differential expression
(DETs) from the US1 baseline are represented for each month, developmental stage, and site. DETs were defined as
protein-coding transcripts with |log2 fold change| >1 and adjusted p-value <0.01. (E) Number and percent of DETs
shared between and unique to the effluent and DS1 sites in each month and developmental stage. (F) Number and
percent of DETs shared between and unique to January and May at both developmental stages and sites. Callout
boxes indicate the number of shared DETs up- and downregulated in both months (white) and additionally at both
the effluent and DS1 sites (red).

The comparatively few DETs (vs. US1) shared between months at the same site and
developmental stage highlights the influence of seasonal differences in stream chemistry. Only
8 to 12 % of DETs were shared across month, and those with consistent fold change directions
represented at most 1% of DETs (Figure 2.1f). Effluent concentrations of antidepressants (4152
ng/L) and antihistamines (3838 ng/L) were 30 and 36% higher in May compared to January, and
H2 antagonists (917 ng/L) and antivirals (841 ng/L) were three times higher. In January, effluent
concentrations of antibiotics (992 ng/L) and the corrosion inhibitor methyl-1H-benzotriazole
(713 ng/L) were three times higher than in May and beta-blockers at 980 ng/L was 28% higher
(Figure A.3, Table A.3).
Among directionally consistent DETs shared between months, 51 were common to both
the effluent and DS1 sites in the 3 dpf exposures, and 3 were common to both sites in the 6 dpf
exposures. These transcripts appear robust to seasonal variation in Muddy Creek stream
chemistry, capturing impacts related to metabolism and autophagy, and could serve as early
markers of WWTP effluent exposure (Figure 2.2). Among the 39 upregulated 3 dpf DETs shared
at the effluent and DS1 sites were multiple transcripts involved in metabolic processes that
generate cellular energy including suclg2, gnpda2, slc2a2, g6pca.2, tmem86b, aldh1l1, abhd14b,
cers3a, and abcb11b (Figure 2.2). Growth inhibition and disruption of metabolic pathways are
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commonly observed responses to pharmaceutical exposures, although contrary to these
results, gene expression is often suppressed.112,113 For example, downregulation of two genes
involved in the citric acid (TCA) cycle, succinate-CoA ligase (suclg2) and glucose-6-phosphatase
a (g6pca.2), has been reported in response to neuro-pharmaceutical and antibiotic exposures.
The tricyclic antidepressant, mianserin, downregulated g6pca.2 and energy metabolism KEGG
pathways113 in 3 dpf larval zebrafish. Similarly, suclg2 was downregulated in adult Chinese rare
minnow (Gobiocypris rarus) (1 μg/L carbamazepine)114 and in 3 dpf zebrafish larvae (antibiotic
mixtures of 0.1-100 μg/L), where it was established as a highly influential hub gene.115
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Figure 2.2. Expression of the 51 protein-coding DETs (adjusted p-value <0.01 and |log2 fold change|>1) common to
both January and May 3 dpf exposures. DETs were up- or downregulated at both effluent and DS1 (vs. US1).
Expression is represented as the z-score of vst counts by transcript.
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2.3.2 Common transcripts suggest important new wastewater exposure biomarkers.
Transcripts related to autophagy were also among the 39 upregulated DETs common to
all 3 dpf exposures. The careful regulation of autophagy enables the rapid recycling of cellular
components required for the many changes in cellular architecture fundamental to
embryogenesis.116 Regulation of autophagy is also relevant to xenobiotic exposure scenarios in
which protein damage occurs or disruptions to cellular energy production require recycled
amino acids as a replacement energy source for the TCA cycle.117 Autophagy related genes
upregulated at the January and May effluent and DS1 sites included mannose receptor C
(mrc1b) and etoposide induced 2.4 (ei24). Mannose receptors are involved in phagocytosis and
endocytic pathways, and mrc1b specifically enables the migration of microglia to the optic
tectum during the development of the brain lymphatic system in zebrafish embryos.118,119 Ei24
is a transmembrane protein in the endoplasmic reticulum that enables crosstalk between the
ubiquitin-proteosome system and autophagy, both of which carry out protein recycling, the
former by ushering ubiquitin-tagged proteins to the proteosome and the latter through
transport of large proteins to lysosomes.117 Disruptions to normal cellular functions have been
described in response to downregulation of these genes,117,119 so the significance of their
upregulation may merely be that an increased need for amino acid recycling requires
upregulation of autophagy promoters.
Collagen XIV alpha 1b (col14a1b) was downregulated in the 6 dpf exposures in both
months at the effluent and DS1 sites. It was the only 6 dpf DET of a principal isoform with
consistent fold change direction month and site. Collagen XIV proteins regulate collagen fibril
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formation at all life stages, but col14a1b is only expressed during embryogenesis, likely involved
in the formation of embryonic basement membranes and undifferentiated epithelia.120
2.3.3 Significant differences in expression signatures across months reflect chemical
mixtures.
Differences in expression signatures between US1 and the effluent and DS1 sites were
more pronounced in May vs. January, with 2.9 to 4.6 times more DETs (vs. US1) at each site and
developmental stage, a greater number of which contributed to enriched functional terms and
pathways (Figure 2.1d). Enriched KEGG pathways and biological process Gene Ontology (GO:BP)
terms involving the musculoskeletal system, heart, cell adhesion, metabolism, and embryo and
larval development were downregulated in January and upregulated in May (Figure 2.3). Nearly
all enriched GO:BP terms in 3 and 6 dpf May exposures were upregulated (180 to 238) and few
were downregulated (0 to 11) (Table S5). In contrast, the only enriched GO:BP terms in January
resulted from downregulated DETs. The reverse mirroring of up and downregulated terms in
January and May suggests the possibility of divergent impacts from chemical mixtures between
months as well as the possibility of a shift in US1 water chemistry.
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Figure 2.3. Statistically significant (adjusted p-value <0.05) overrepresentation of biological pathways and
processes of differentially expressed transcripts (DETs, |log2 fold change| >1 and adjusted p-value <0.01) up- and
downregulated at effluent and DS1 (vs. US1, the upstream reference) in zebrafish embryo exposures (Jan 3 dpf, Jan
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3 dpf, May 6 dpf). Overrepresentation analysis of Kyoto Encyclopedia of Genes and Genomes64 (KEGG) pathways
and Gene Ontology (GO:BP) was performed in clusterProfiler (R v4.0.1). (A) Overrepresented KEGG pathways from
each set of DETs (vs. US1). (B) Selected overrepresented GO:BP terms from each set of DETs (vs. US1).

Although no major biological pathways or processes were unique to the January
exposures, several were unique to May. Among upregulated DETs, unique KEGG pathways and
biological processes included adrenergic signaling in cardiomyocytes, cell adhesion, ECM
receptor interaction, neurological development functions, amino acid biosynthesis and
metabolism, and the MAPK, FoxO, and PPAR signaling pathways (Figure 2.3). Regulation of
hormone levels, phototransduction and other visual processes were downregulated in May,
primarily at 3 dpf, although phototransduction was also upregulated in the January 6 dpf
exposures.
The MAPK and adrenergic signaling in cardiomyocytes pathways were upregulated at
both developmental stages in May and could be related to several pharmaceuticals present in
Muddy Creek effluent including metformin (antidiabetic), beta-blockers, and SSRI/SSNRIs.
Metformin regulates glucose levels through inhibition of ATP production within the
mitochondria which activates the energy sensing AMP kinase (AMPK) pathway and leads to
glucose uptake and fat oxidation in the liver.49 Metformin also impacts other energy dependent
pathways, including the mitogen activated protein kinase (MAPK) signaling pathways, which
regulate cell proliferation, apoptosis, glycolysis,121 and adrenergic signaling pathways
responsible for regulation of metabolic “fight or flight” responses to stress. The enrichment of
the MAPK, heart contractions/adrenergic signaling in cardiomyocytes, and
glycolysis/gluconeogenesis pathways in the May 3 dpf exposures is suggestive of metformin as
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a candidate explanatory factor. Two out of those three pathways were enriched at 3 and 6 dpf
in January and 6 dpf in May.
In the May 3 dpf exposure, 54 transcripts were deregulated across the adrenergic
signaling in cardiomyocytes pathway, including ion membrane transporters, the actin-myosin
crossbridge, and a β2-adrenergic receptor (adrb2b) involved in regulation of heart rate (Figure
A.4b). Adrenergic signaling receptors are involved in a wide variety of biological processes
including heart contractions, lipolysis (breakdown of triglycerides), blood flow, and regulation
of metabolism,122 which could involve interaction with the FoxO and MAPK pathways, both
disrupted in the May 6 dpf exposures. Although few studies have examined sublethal impacts
of exposure to beta-blockers on fish, propranolol at 80 ng/L is reported to reduce larval
zebrafish heart rate123 and atenolol at 0.01 nM (2 ng/L) can block epinephrine-stimulated
glucose production in trout hepatocytes.124 Total concentrations of the three beta blockers
measured at the Muddy Creek effluent site (metoprolol, atenolol, and propanolol) exceed these
levels by orders of magnitude (i.e., 980 ng/L in January and 701 ng/L detected in May) (Figure
A.3). Although enrichment of the adrenergic signaling pathway was unique to the May
exposures, the enrichment of the cardiac muscle contraction pathway in the January exposures
involved many of the same transcripts (Figure A.5). The dysregulation of cardiac processes
across month and developmental stage is consistent with the presence beta-blockers.
The antidepressant, venlafaxine, also has documented impacts that span many
interconnected pathways and biological processes and was one of the top pharmaceuticals
detected in Muddy Creek with effluent concentrations at 1240 ng/L (January) and 1550 ng/L
(May) (Figure A.3). Venlafaxine is known to disrupt neurological development,125 MAPK
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signaling,126 metabolism,84 stress response, locomotor activity,127 and adrenergic signaling.124,125
Although the exact mechanism of action on the MAPK pathway is unclear, the direct impact of
venlafaxine may result from upregulation of brain derived neuroeffector (BDNF), which initiates
a phosphorylation cascade that reaches the MAPK pathway.126 Impacts to larval fish have been
documented at low concentrations; an 80-hour exposure of larval zebrafish to just 80 ng/L of
venlafaxine was sufficient to increase embryonic malformations, including loss of
pigmentation.128 Pigmentation abnormalities in larval zebrafish have been associated with
delayed development and reduced fitness in other studies, which has been suggested as a
possible link to beta-adrenergic signaling given the presence of adrenergic receptors on
pigment-producing melanophores.129 The lack of similar biological pathway and process
enrichments in January, however, suggests that venlafaxine is not driving enrichment patterns
of DETs between the months examined during this study.
Visual system impacts occurred primarily in the May 3 dpf exposures through
enrichment of the phototransduction KEGG pathway and several other visual GO:BP terms
among downregulated DETs (Figure 2.3a and 2.3b). Transcripts were downregulated across the
phototransduction cascade and included light-sensitive pigments, transducins involved in Gprotein signaling, Ca2+ and Na+ voltage-gated channel proteins, and rhodopsin kinases that
deactivate phototransduction in dark conditions (Figure A.4a). In total 71 unique genes were
enriched among vision-related biological processes at the effluent site and 61 at DS1.
Impaired eye development in fish necessarily impacts neurological functioning, behavior
and metabolic processes, and thus may later impair growth, reproduction, and survival.80 Many
chemicals found in wastewater effluent, including progestins,130,131 antidepressants,132,133
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flame-retardants,134 and pesticides,135,136 have been associated with visual system disruptions
including altered gene expression in the phototransduction cascade. Progestins such as
dydrogesterone130 and norethindrone131 have been shown to disrupt circadian rhythm, eye
development, and the phototransduction cascade during zebrafish development.
Antidepressants are known to alter visual motor response in larval fish,133 and high doses of
paroxetine and fluoxetine (100 μg/L) also disrupted phototransduction.132 At 1 μg/L, the
organophosphorus flame retardant triphenyl phosphate has been shown to disrupt phototactic
behavior in larval zebrafish and downregulate key photopigment opsin genes, including several
on the phototransduction cascade that were downregulated at the effluent and DS1 sites in the
May 3 dpf exposures (rho, opn1mw1, opn1mw2).134 The pyrethroid pesticide cypermethrin
impairs eye development in fish embryos135 and disrupts gene expression across the developing
visual system, including the phototransduction cascade (downregulated).136,137 The fatty acid
binding protein 11b (fabp11b), downregulated by cypermethrin,136 plays an important role in
fatty acid metabolism in the developing eye of zebrafish embryos, and was also significantly
downregulated (p<0.01) in the May 3 dpf exposure with log2 fold changes of -2.4 and -2.5 at
effluent and DS1, respectively.
2.3.4 Upstream estrogenicity signal in May identified by transcripts.
Notable estrogenicity was observed at all sites during monthly collections. This included
an estrogenic signal with unknown origins detected by the BLYES assay in May at US1 (Figure
2.4a). The greatest estrogenic measurement of 3.7 ng/L E2Eq(BLYES) occurred at the US1 site in
May, the highest at any of the Muddy Creek field sites over the 12-month study period. This
measurement was more than double the estrogenicity of US1 in January at 1.52 E2Eq(BLYES) ng/L,
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which had the lowest measured estrogenicity among stream sample exposures used for RNA
sequencing. Estrogenicity was most variable at US1, which had the highest and lowest E2Eq
values of all sites over the 12-month sampling period (1.03 E2Eq ng/L in November 2017 and 3.7
ng/L in May 2018) (Figure 2.4a). In contrast, estrogenicity measurements below US1 ranged
from 1.54 to 1.88 E2Eq(BLYES) ng/L at the effluent and from 1.55 to 2.37 E2Eq(BLYES) ng/L at DS1
(Figure 2.4a). The January and May US1 samples thus represent contrasting estrogenic stream
gradients with US1 estrogenicity lowest of the three sites in January and highest in May.
Current predicted no effect concentrations (PNOECs) range from 0.1 to 0.73 ng/L
E2Eq(BLYES)138,139 thus identifying the baseline estrogenicity of Muddy Creek as high and of
biological significance. The impact of estrogenicity on the zebrafish transcriptome was
suggested in comparisons of the 3 and 6 dpf exposures at US1. Functional enrichment of
transcripts with significantly higher expression at 6 dpf (vs. 3 dpf) resulted in few typical
developmental processes in May but many in January (Figure 2.4c). There were several
pharmaceutical detections at US1 in both months,1 however, not at levels that could explain a
strong estrogenicity signal or 6 dpf developmental impacts. In May, more chemicals were
detected at US1 and concentrations tended to increase relative to January, but none of the
detections in either month were at levels known to be bioactive (Figure A.3). An alternative
explanation of the high estrogenicity signal at US1 could be the presence of undetected
analytes. Strategic non-targeted chemical analysis could help resolve cases in which distinct
bioeffects occur but are not explained by the chemicals detected in a targeted analysis, which
would be particularly useful for field reference sites.140
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Figure 2.4. A) Calculated estrogen equivalents (E2Eq in nanograms per liter) relative to 17 b-estradiol of extracts
from monthly 1-liter grab samples collected at baseflow, September 2017-August 2018. (B) Percent of total
differentially expressed transcripts (DETs) with higher upstream reference (US1) expression at 3 dpf (vs. 6 dpf) and
6 dpf (vs. 3 dpf) unique to and shared between January and May (log2 fold change >1 between developmental
stages and B-H adjusted p-value <0.01). Colors represent the quantity unique to or shared between months. (C)
Overrepresentation of biological process (GO:BP), molecular function (GO:MF), and cellular component (GO:CC)
Gene Ontology terms and KEGG terms (adjusted p-value <0.05) among DETs with significantly higher expression at
3 or 6 dpf at US1 in January and May.

2.3.5 Stage of development is a significant determinant of transcriptomic response to
upstream estrogenicity signal in May.
Differential gene expression and PLS-DA suggest that exposure to the estrogenicity
signal at US1 may impact 3 and 6 dpf larvae differently and in ways that are likely due to
developmental changes in early fish development. The transition from a rapidly growing
embryo to a free-feeding larva leaves tell-tale signatures in the transcriptome that should be
evident in comparisons of 3 and 6 dpf.93,141 To determine whether these signatures of normal
development occurred in the January and May exposures at the US1 reference site, we
identified overrepresented KEGG pathways and GO terms among transcripts differentially
expressed at 3 dpf (vs. 6 dpf) and 6 dpf (vs. 3 dpf) as indicators of developmental progression.
At the US1 baseline in both months, there was a consistent overrepresentation of GO terms
and KEGG pathways among genes associated with development at 3 dpf.141 These
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overrepresented terms encompassed many biological processes related to this period of rapid
cell proliferation and differentiation. Of the 105 biological process GO terms enriched in both
January and May 3 dpf transcripts, 80 related to DNA replication and the cell cycle (Figure 2.4c).
Estrogenicity appeared to impact the 6 dpf transcriptome and alter developmental
progression in the 6 dpf May exposures. KEGG pathways and GO term enrichments indicative of
normal development at 6 dpf (vs. 3 dpf) were present in January, but not in May, which may
reflect the sensitivity of this developmental stage to estrogenic exposures (Figure 2.4c).
Although more DETs with higher expression at 6 dpf (compared to 3 dpf) were shared between
months, there were relatively few shared enrichments (Figure 2.4b); however, several shared
molecular functions (GO:MF) related to protein metabolism, an expected contrast between the
fully functioning gut of 6 dpf larvae and the yolk-dependence of 3 dpf embryos.93,141
Enrichments unique to January encompassed a wide variety of processes known to be more
relevant to the 6 dpf life stage (vs. 3 dpf) and related to the immune system, response to the
environment, circadian rhythm, visual system, bile synthesis, ammonium transport, lipid
transport, all of which are required for hunting and free-feeding. Digestion and metabolism, the
most prevalent category, made up nearly half of all enriched terms (25/58).
In contrast, the few enrichments unique to May transcripts with higher expression at 6
dpf (vs. 3 dpf) were narrow in scope and related to amino acid catabolism and biosynthesis,
glycerolipid metabolism, and membrane transporters. Overall, May lacked enrichment of genes
linked to typical developmental pathways. Pathways related to the visual system and muscle
development were absent and there were notably few related to digestion and metabolism,
which represented less than 50 genes total. Although this analysis suggests the possibility that
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that normal development at 6 dpf was disrupted, there are many other factors unaccounted for
that could contribute to the contrast between January and May comparisons. An additional
consideration is that synchronicity across individuals during development lessens as
development progresses into the larval stage.94 Thus, the 3 dpf developmental stage may serve
as a more reliable model for relating the bioeffects of effluent exposure to chemical
composition.
2.3.6 Environmental implications.
A goal of our research was to identify common transcriptome markers of effluent
exposure in larval zebrafish as well as markers specific to developmental stage and seasonal
variation in pharmaceutical mixtures. Ultimately, we see that variation in chemical signatures
across months is recapitulated in gene expression, and that even with estrogenic input
observed in the US1 reference site, the transcriptome can still reveal key relationships between
pathways and processes relevant to understanding environmental effects of chemical
exposures. There were several dozen significant DETs from the 3-day exposures that had
consistent fold change directions in both months, including transcripts with key roles in embryo
and larval fish development such as mrc1b and ei24 and many related to energy production and
metabolism. These transcripts do not represent therapeutic or other known targets of any
particular chemical detected, and rather likely represent the off-target impacts that many
pharmaceuticals have on metabolic functioning and fish development and therefore could
provide new biomarkers for monitoring the impact of effluent. In addition, the disruption of
normal developmental pathways in the 6 dpf larval fish underscores the need for biomarkers
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specific to developmental stage and indicates that specific developmental pathways may serve
as biomarkers of endocrine disruption.
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Chapter 3: In vitro predictions vs. in vivo reality:
Molecular impacts of exposure to WWTP effluent in
zebrafish embryos are partially predicted from
aggregated ToxCast data
3.1

Introduction
Over the past several decades, the ability to detect environmental contaminants at very

low concentrations (ng-ug/L) has vastly outpaced ability to interpret their biological
significance.14 While in vivo toxicological studies provide the most robust effects data for
environmental contaminants, the need for relevant bioeffects data is far too vast and
immediate for the traditional whole-animal approach to toxicology.142 The problem of
prioritizing chemical contaminants found at low concentrations is compounded in aquatic
environments where complex mixtures exist and can evolve rapidly over time1,143 with potential
impacts to many biological pathways. In the case of wastewater effluent, which serves as a
consistent source of pharmaceuticals, pesticides and other compounds with designed
bioactivity, sublethal endpoints that capture changes in growth and behavior are needed as
effects of this nature have potential to decrease resilience and impact reproductive success.78,84
Pharmaceutical mixtures in wastewater effluent have been shown to harm organisms
and aquatic ecosystems,144 and variation and complexity of exposure conditions make tools
that assess bioeffects and predict exposure risk critical to the task of prioritizing contaminant
mixtures that may pose harm to aquatic organisms. The discovery of potent endocrine
disrupting effects in environmental contaminants in wildlife near the turn of the century
galvanized interest in assessing the environmental safety of the tens of thousands of chemicals
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known to be in circulation.42,58 Evaluating the safety of so many chemicals required a shift to
high throughput screening (HTS) methods as traditional animal toxicity testing would not have
been feasible at such a scale due to the time and resources required. The ToxCast and Tox21
programs (hereafter referred to as ToxCast) were established to meet this need through the
use of highly standardized in vitro HTS assays in which endpoints and dose-response curves are
comparable between assays and chemicals.64,145 ToxCast assays evaluate the bioactivity of
individual chemicals over a wide range of assays designed to detect effects at the cellular and
molecular level across over 300 signaling pathways.146,147 To date, over 9,000 chemicals have
been tested in at least some of the 1473 assays across 15 different platforms.148 These
platforms are primarily cell-based in assay design, with one biochemical-based platform and
one whole-organism (zebrafish) platform. Assay endpoints include non-specific effects (e.g.,
cytotoxicity, oxidative stress, cell morphology changes) and specific pathway-based effects
measuring things like nuclear receptor activity (e.g., androgen receptor, aryl hydrocarbon
receptor). The interpretive value of this data has increased with the expanding universe of
adverse outcome pathways (AOPs), which seek to build linear models linking specific molecular
initiating events resulting from chemical exposures to responses at progressively higher levels
of biological organization and then to an adverse outcome at the organismal level.149
ToxCast data has been successfully used to prioritize chemicals and bioeffects
concerning human and wildlife exposure in many contexts.66,100,150 Nevertheless, several factors
limit the interpretive strength of ToxCast predictions in aquatic ecotoxicology. Some of these
limitations include a lack of species representation (nearly all cell-based assays are mammalian)
and the fact that pharmaceuticals have less assay coverage than needed given the specificity of
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their design. Additionally, while ToxCast data is rich in molecular effects data, standardized
phenotype data are still needed to connect those effects to key events and adverse effects in
associated AOPs. Although ToxCast endpoints encompass nearly 400 unique gene targets and
148 AOPs, disruptions within a biological pathway are not uniform and assays can miss
consequential biological responses. Given these limitations, in vivo exposures with aquatic
species are needed to compare to ToxCast predictions and to identify biological effects that
should be prioritized in the ongoing project of expanding biological pathway coverage in new
ToxCast assays. Transcriptomics and other non-targeted ‘omics data provide opportunity to
identify activity across all biological pathways and confirm activity within genes and pathways
of interest.
The goal of this project was to use aggregated ToxCast assay data to identify the
potential biological impacts of detected chemicals, both individually and in mixtures, as
chemical composition evolves spatially over a 5 km stretch of an effluent-dominated stream
and seasonally across seven monthly sampling events. Impacts predicted by ToxCast were
compared to gene expression patterns previously identified in an RNA sequencing experiment
of larval zebrafish exposed to environmental water samples taken from sites along an effluent
dominated creek in Iowa (January and May 2018). Additional targeted gene expression in
exposure to samples from seven monthly sampling events between January and August 2018
was also used in conjunction with ToxCast predictions to identify potential chemicals and
mixtures over three seasons that may pose harm to larval fish.
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3.2

Materials and Methods

3.2.1 Study Sites and Water Sampling
Muddy Creek, an effluent-dominated stream in Coralville, Iowa (latitude 41°42ʹ00ʺ,
longitude 91°33ʹ46ʺ) was the field site for this study as described in Chapter 2. Additional
description of the field site is available in a prior publication as are complete water sampling
and chemical analysis methods.1 All chemical data used in this study has been publicly released
and is available online.111 In brief, Muddy Creek has a low annual baseflow and a 22.5 km2
drainage area composed of mixed suburban (60%) and agricultural (24.5%) land uses.1 The
stream receives 0.061 m3/s from the North Liberty WWTP,96 which accounts for 80-90% of
streamflow below the effluent outfall. Streamflow ranged from 0.034 to 0.19 m3/s (median
0.061 m3/s) on the actual sampling time points used in this study (January-August 2018) at the
U.S. Geological Survey (USGS) gaging station (station ID 05454090; DS2). Monthly grab samples
used for chemical analysis and zebrafish embryo exposures were taken using the single vertical
at centroid-of-flow method97 during baseflow conditions between January 2018 and August
2018 from four USGS sampling sites: (1) 0.1 km above the WWTP outfall (US1), (2) the effluent
outfall (effluent), (3) 0.1 km below the outfall (DS1), and (4) 5.1 km downstream from the
outfall at a USGS gaging station (DS2) (Figure A1).
3.2.2 Chemical data
The chemical data used in this study consists of previously reported data collected and
analyzed by USGS in which all sampling procedures and analytical methods are fully described
in prior publications.1,111 Samples were collected at the four USGS sampling sites described
above and analyzed for 113 pharmaceuticals and CECs at the USGS National Water Quality

37

Laboratory (NWQL, Denver, CO). Chemical concentrations reported as estimated are values
between the limit of quantitation and long-term method detection limit and were included as
detections in the analyses described.
3.2.3 Zebrafish embryo exposures
Fertilized embryos from wild type 5D zebrafish (University of Wisconsin-Milwaukee)
were exposed to water samples from each of the four Muddy Creek sampling sites and a
dechlorinated tap water control for 6-day exposures to stream water samples. Animal care
protocol and embryo exposure procedures are fully described in Chapter 2. Briefly, groups of 20
fertilized embryos were screened for developmental uniformity at 6 hours post-fertilization and
placed in petri dishes with 30 mL of sample water from each stream site. Petri dishes were
incubated at 27°C under a 16:8-hour light/dark schedule for 6 days. Surviving larvae from each
dish were pooled into 1.5 mL tubes and frozen in liquid nitrogen for subsequent RNA
extraction. All samples from the monthly exposures between January and August 2018 were
used in gene expression assays for the study except for March 2018, which was excluded due to
size constraints. The upstream site 100 meters above the outfall (US1) was used as an in-stream
baseline for assessing the relative impact of wastewater effluent exposure.
Total RNA was use isolated using the standard protocol for Direct-zol RNA MiniPrep
(Zymo Research, R2051). Whole embryos were homogenized in TRIzol with a pestle in a
microfuge tube, and RNA was purified on Zymo-Spin IIC columns. Sample purity was assessed
with a NanoDrop spectrophotometer (Thermo Fisher Scientific, Waltham, MA) with acceptable
wavelength ratios of 1.8-2.0 for 260/280nm and 2.0-2.2 for 260/230 nm and quantified on a
Qubit 2.0 fluorometer (ThermoFisher Scientific, Waltham, MA).
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3.2.3 Gene expression
nCounter. Nanostring nCounter Technology (Seattle, Washington) was used to directly
quantify transcript abundance for 46 genes associated with exposure to pharmaceuticals and
other wastewater contaminants in samples from seven monthly 6 dpf exposures (JanuaryAugust 2018, excluding March 2018). The nCounter platform provides transcript quantification
comparable to quantitative real-time polymerase chain reaction (qPCR) in sensitivity and
specificity with the advantage of being able to multiplex up to 800 gene targets per sample. The
nCounter analysis platform directly evaluates transcript abundance through imaging colorcoded probes designed to capture specific mRNA targets such that no conversion to cDNA is
required.151 Probes were selected based on the RNAseq data presented in Chapter 2 and other
literature152,153 and represent genes associated with endocrine disruption from exposure to
CECs,152 disruptions to cellular energy metabolism, and circadian rhythm. CodeSet details for
the 50 gene targets (46 genes of interest and 4 housekeepers) are provided in Table 3.1. The
nCounter assay was conducted per manufacturer protocol using 50 ng RNA per sample and 24hour hybridizations. nSolver Analysis Software 4.0 was used for quality control of the transcript
abundance data. Eight negative control probes were included by the manufacturer to capture
non-specific binding. As per manufacturer guidance, the negative control probe with the
highest counts was removed from each sample if it registered more than twice the number of
counts as any other negative control probe within a sample. The limit of detection (LOD) was
determined separately in each exposure month and site as the geometric mean of the negative
control probes plus two standard deviations. The LOD ranged from 21.5 to 35.7, and genes with
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counts below the LOD in any sample for a given comparison between a stream site and the
upstream reference (US1) were excluded from further analysis.
The R package NanoStringDiff154 (v 1.20.0) was used to normalize counts to
housekeeping genes, negative control probes, and positive control probes, which account for
pipetting errors and other lane differences, and for differential expression analysis.
Housekeeping genes included acidic ribosomal phosphoproteins (arp), eukaryotic translation
elongation factor 1 alpha 1, like 1 (eef1a1l1), hypoxanthine phosphoribosyltransferase 1
(hprt1), and actin beta 1(actb1), which were selected based on literature152,155 and assessed for
stability using NormFinder.156 The stability values of housekeeping genes ranged from 0.05 to
0.08, which indicates low variation between sample subgroups. Because nCounter transcript
abundance data is count-based, a normal distribution cannot be assumed for low-expression
genes with counts close to zero. Thus, statistical methods used for other count-based transcript
abundance data (e.g., RNAseq) are most appropriate. Differential expression between stream
site and the reference (US1) was calculated in NanoStringDiff154 which uses a negative binomialbased model and an empirical Bayes shrinkage method to estimate a dispersion parameter for
each gene. A gene was considered to have significant differential expression between stream
site and the US1 reference if the magnitude of its log2 fold change exceeded 0.75 with a
Benjamini-Hochberg (B-H) adjusted p-value below 0.05.
RNA sequencing data. RNA sequencing data from the 6 dpf larval zebrafish exposures at
the US1, effluent, and DS1 sites in January and May were used as described in Chapter 2.
Differentially expressed transcripts (DETs) in comparisons of the effluent and DS1 sites to the
upstream reference (US1) were considered significant at a log2 fold change threshold of 1 (B-H
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adjusted p-value < 0.01). Statistical significance and biological relevance of functional
annotation groups represented among DETs was established through overrepresentation
analysis (B-H adjusted p-value<0.05).
Table 3.1. Genes and target sequences used in the custom Nanostring CodeSet. Melting temperatures for the
reporter probes (Tm RP) and capture (Tm CP) probes are indicated in degrees Fahrenheit. Housekeeping genes are
noted with an asterisk.
Accession Number Gene

Tm CP Tm RP Target Sequence

NM_131846.2

ache

80

81

TTAATCTGTTGTAAGCATAAGAGTGCAGATCAAAGAAAAGGGAAAACTGATG
ACCATAACCCTTAATAGTCTCTTTTCAGAACGGCAATGGCTGCCAAAG

NM_131031.2

actb1*

83

84

AGGAAGTGCTTCTAAACAGAACTGTTGCCACCTTAAAATGGCCATGCAATGA
GATTCAAACGAACGACCAACCTAAACCTCTCGAACAAGATGACATCAG

AF134852.1

arp*

85

81

CACCGGGCTCGGTCCTGAGAAGACCTCTTTCTTCCAGGCTTTGGGAATCACCA
CCAAGATCTCCAGAGGAACCATTGAAATCTTGAGTGACGTTCAGCTT

NM_001024816.2

ahr1b

85

81

ACAAAACTGAGAACTGGATCCATACACCATTGTCTCAAGTGCCTACAACAGA
ATCTGAGACAGCTAACTTTAACCAGCATGATACTACTTTGGTGAACTC

NM_131128.1

apoa1a

85

82

GAGCAGCACCTCTCAGGGCTTAATCATGAAATTCGTGGCTCTTGCACTGACTC
TTCTCTTGGCCTTGGGTTCCCAGGCCAATTTGTTCCAGGCTGATGCC

NM_001083123.1

ar

83

80

TTCCTCTGTATGAAGGCCCTCCTCCTGTTTAGCGTCATTCCAGTGGAGGGGCT
GAAGAGTCAGAAGTATTTTGATGAGCTGCGTCTGACGTACATAAACG

NM_199611.3

arg2

86

84

AGAGATGTGGATCCAGGCGAGCATGTATTCCTAAAGACCCTGGGAATTCAGT
ACTTCTCCATGCGGGACATTGACAGAATGGGCATTCAGAGAGTAATGG

NM_001271393.1

camk2b1

83

81

AAATACGGATAAATAAGGCCTCAGCGAGTCGTCTGTGAAACGCCATGCTTTC
CGTCGCACCTTCCCAGTGTCAATAACGTTACACTGAATCACCGTCCTC

NM_001114708.2

camk2d1

81

84

GTTCAACGCCAGGAGGAAGCTTAAAGGTGCTATTCTTACTACCATGCTTGCCA
CACGGAACTTCTCAAGCAAAAATCCATACAAGAAACCTGATGGTGTC

NM_130912.2

cat

81

83

GGGATTTTTGGAGCTTGCGTCCTGAATCGCTGCACCAGGTGTCTTTCCTGTTC
AGTGATCGAGGGATTCCCGATGGCTACCGTCATATGAACGGATACGG

NM_131786.2

cry2

85

84

TACATGTATGGAAGGGTGGTGAGACTGAAGCCCTGGAAAGATTAAATAAAC
ACTTGGATAGGAAGGCCTGGGTAGCAAATTTTGAGAGGCCTAGAATATC

NM_131788.1

cry5

89

79

AGGCCATGGGTCACCCTAAAAAACCTATTCCTGCTCCAACCAACGAGGACAT
GCGAGGTGTGTCCACTCCACTTTCTGATGATCATGAAGAAAAGTTTGG

NM_212806.3

cyp17a1

84

82

CGTGGATTTTGCAAAGGTTTACTCTGGAGATGCCCACTGGCCAGCCTCTGCCT
GACCTCCAGGGCAAGTTTGGCGTGGTTCTTCAACCCAAGAAATTCAA

NM_131154.3

cyp19a1a

85

85

CTCTACGTTTTCACCCGGTCGTGGACTTCACCATGCGGCGGGCGCTGGATGAT
GATGTCATCGAGGGCTACAACGTGAAGAAAGGAACAAACATCATACT

NM_131642.2

cyp19a1b

80

81

AACCTAATCCTGAACATTGGACGCATGCATAAGACAGAGTTCTTCAAAAAACC
CAACGAATTCAGCTTGGAGAACTTCGAGAACACTGTTCCCAGTCGTT

NM_131879.2

cyp1a

84

82

ACGAAAACTCCAACCTGCAAGTGTCCGATGAGAAGATCGTAGGAATCGTCAA
TGACCTATTCGGAGCCGGTTTCGACACTATCAGTACGGCTCTGTCCTG
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Accession Number Gene

Tm CP Tm RP Target Sequence

NM_213067.1

dusp1

78

80

CCAGACGTTTGCTTGTCTGTAAACAAACAGCGAAATACCTCATGTGTCTGTAC
TGTTGTCAGTCCGGTAAGAGTCCTCTTCCCTTAAGCACTACTAACAG

NM_131263.1

eef1a1l1*

84

81

GAAGGCTGCCAAGACCAAGTGAATTTCCCTCAATCACACCGTTCCAAAGGTT
GCGGCGTGTTCTTCCCAACCTCTTGGAATTTCTCTAAACCTGGGCACT

NM_200016.1

eif3d

82

79

ATGTGCTGCACACGCTCTGTCAACTCCTGGGATATTATCGTTCAGCGTGTGGG
CAACAAGCTCTTTTTCGACAAGAGAGACAACTCTGATTTTGATCTGC

NM_152959.1

esr1

89

88

GAGATGCTGGACGCTCAGCGGTTCCAGTCTTCAGGGAAGGTGCAGCGAGTG
TGGTCTCAGAGCGAGAAAAACCCTCCATCTACACCCACAACCAGCAGCA

NM_180966.2

esr2a

82

84

GTCACACAAACACAGTACTTAAGGATGATCTGTAGTTTCGGGAGGATGGACA
ACCAAAACACCCACATAAAAGCAAGGAGTAGGATTTCACAAGACGAAA

NM_174862.3

esr2b

81

89

CCCTGAACAATTGGTTAGCTGTATTCTAGAGGCGGAGCCACCTCAAATTTACC
TGAGAGAGCCGGTGAAAAAGCCATACACTGAGGCTAGCATGATGATG

NM_205569.1

fosab

85

89

GCTCAAAGAAAAAGAGAGGTTAGAGTTCATCCTCGCCGCACACAAACCCATC
TGCAAGATCCCGGCCGACGCCAGCTTCCCAGAGCCGTCCTCCTCTCCC

NM_131585.1

fth1a

85

89

ACCCTCACATGTGCGATTTCATTGAGACACACTACTTGGACGAGCAGGTCAAA
TCCATCAAAGAACTGGGCGACCATGTGACCAACCTGCGCCGCATGGG

NM_001077326.1

gabra1

89

89

ACTCGAGGGGCGGCGCAGTCCGTGGTCGTGGCTGACGATGGTTCCCGTCTCA
ACCAGTATGACTTGATGGGACAGAGCGTAGACTCGGGCGTGGTGCAGT

NM_131869.2

gnat2

81

82

CCACGGACACAAAGAACGTCGAGATTGTGTTTAACGCCGTGACAGACATTAT
CATCAAAGAAAACCTTAAGGACTGCGGTCTGTTCTAAACACCATCCAC

NM_199967.1

gngt1

84

80

GCCCATGGACACCTGTTAAAAACGTAATACTTGCTGGAATTCGCTGCCCAAAA
AAGGACATTCTCAAACACGGATAGACGTTGGTTAACTCTAAATGGCT

NM_001204332.1

gngt2b

89

86

CTCCTAGCAGGACACAACACACTTCTCTGACTGCCGCAGGGCCCGACAATCCA
CAGTCAGGATGGCTCGGGACATGTCAGATAAAGAAATCCTGAAGATG

NM_182887.2

gnrh3

84

85

CAATGGAGCAGCTTTCACCAATACACATAGTGAATGAGGTGGATGCTGAAGG
TTTGCCTCTGAAAGGACAAAGATTTCCAGACAGACGGGGAAGAGTGTA

NM_001007281.2

gpx1a

81

85

AAATACGTCCGTCCTGGAAATGGCTTCGAGCCCAAATTCCAAATTCTGGAGA
AGCTGGAAGTGAATGGTGAAAACGCCCACCCTCTGTTTGCGTTCCTGA

NM_001327762.1

gstt1a

80

82

TGGATTCTGCCTTGGAGGATCTCAACATGTCTTTGAAGATCTTTGAGGACAAA
TTTCTGCAGAGCAGGCCCTTCATAATAGGGGATAAAATATCTCTGGC

NM_001310042.1

hif1ab

82

80

CCCAGTGGAACCAGACATCAGTTCTGAATTTAAACTCGACCTGGTTGAGAAA
CTGTTTGCTATTGATACCGAAGCAAAGACACCTTTTTCCACCCAGCCC

NM_212986.2

hprt1*

85

80

CAGGTTAGTGGTCCTCCACTCAGGGTCTCTGGTGAGGTGTGTGCTGTTAATG
CACCTTACATTTACATTCACTTATACCTCCACAGGCACCCAACAAACA

NM_205584.2

hsd17b1

85

80

CCTCCATGGACGGCTCTCAGTACATCAGAGCAATGAGCAAACTCATCTTCTCT
TCTCCCGGTACAGATGCACAGAAATGATGCCAACACAGAGTTTCATT

NM_212797.1

hsd3b2

83

86

TCCTTTATATACACCAGCAGCATTGAGGTAGCGTGTCCCAATCGCAGCGGTG
AACCCATCATCAACGGCCACGAGGACACGCCTTACTCCTCTTATCCTA

NM_001098732.1

hspb15

85

82

TGCAAGAAAATACAAGCTTCCGGCTGACTTAGACCTAAAACAGATCAGCTCC
ATGCTGTCTCCAGATGGTGTTCTCTCAGTTGAAGCTCCATTAACGGGC

NM_001098257.2

igfbp1b

86

84

CTCATCCAGCAGGGTCCGTGTCACACTGAGCTTCTCGCGTCTCTGGACGTCAT
CACAGAGTCTCAGCAGGCGTTGGGAGAGAAGTTCACCAGTTTCTACC
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Accession Number Gene

Tm CP Tm RP Target Sequence

NM_131075.1

mt

92

81

TGCGCCAAGACTGGAGCTTGCAACTGTGGTGCCACCTGCAAGTGCACCAATT
GCCAGTGTACAACCTGCAAGAAGAGTTGCTGTTCTTGTTGCCCGTCTG

NM_001020711.3

nr3c1

82

83

TCAGCAACCAGTTACCAAAATTCAAAGATGGGAGTGTTAAACCGCTGCTCTTT
CACCAGAAATGAATCTCCTCCCAACAGCAGGACACGATGCCTTAAAT

NM_214751.1

pck1

89

89

AGGACGGTGAACCGTGTGCTCACCCGAACTCCCGCTTCTGTACGCCGGCCGC
TCAGTGTCCCATCATCGACCCGCAGTGGGAGTCTCCTGAAGGCGTCCC

NM_213192.1

pck2

84

85

TGGTTCCGGAAAGATCAGAAGACTGGCTCCTTTCTGTGGCCAGGATTTGGAG
AGAACGCCCGTGTCCTTGAGTGGATCTTCAAACGATGTGGCCGTACCA

NM_212439.2

per1b

81

80

TTTGGCTCCCACGAAGAGGTTGTGGTCTGTTTGCAAGCTCGATTTGGGCGGA
GATATGGAATACTTCGCTTTAGCCCACTCTGGATTTGACCTCAAGACG

NM_001161333.1

pparaa

80

83

GCTCCTCTGCTCCATCATAATGTCATATTCGCAGGCTGGAGTTGTAGATATGG
GAACGTGGCTAACGAAGTGTAACTTTTAGAGTGGTCTGCGTCATACC

NM_131467.1

pparg

85

81

GAGACAAAGCTTCGGGGTTTCATTACGGCGTTCACGCCTGCGAGGGATGCAA
GGGTTTTTTCCGCAGGACGATTCGCCTGAAGCTGGTGTACGATCACTG

NM_131294.1

sod1

80

83

GGTGTTGCAAAAATTGAAATCGAGGATGCAATGCTAACTTTGTCAGGCCAAC
ATTCTATTATTGGGAGGACCATGGTGATTCATGAGAAGGAGGATGACT

NM_131663.1

star

84

84

CAAACTGAGATTGAGAGTATCAACGGGGAGAAGGTCATGAGTAAAGTCCTG
CCTGGCATTGGAAAGGTTTTTAAGTTGGAAGTGACCCTGGAACAGCAGA

NM_198914.2

sult2st1

86

75

ATGGGACTGAACACCTCATCTGATCTCTCCTGAGCTGCATACATTCACTGTAG
CCTTTGGTGCTCGATTAGTATACAGATGTTTTATCCACTCCAGCATA

NM_131396.1

thraa

86

89

ATTGTGAAGACGTTACACAATCGACCTGAGCCCACCGTGTCAGAGTGGGAAC
TCATTCGTATGGTGACGGAGGCTCATCGGCACACCAATGCCCAGGGCC

NM_131340.1

thrb

80

83

CATTGACAAAGTTACCCGAAACCAGTGCCAAGAATGTCGCTTCAAGAAATGC
ATCGCTGTTGGCATGGCTACAGACTTGGTATTGGATGACAGTAAACGT

NM_001044897.3

vtg1

82

86

AAGTTACTGGCAAGTTTTCTTGGGGTGCGGAGTGCAAACAGTATGCAGTCTT
TGCTAAAGCTGAAGCTGGTGTCCTGGGTGAATTCCCTGCTGCACGTCT

3.2.3 ToxCast bioeffects screening
The 109 pharmaceuticals and degradates measured in Muddy Creek represent a small
fraction of the over 4,500 active pharmaceutical ingredients in current use.157 Globally, over
600 pharmaceuticals and transformation products have been detected in wastewater
effluents.158 The designed bioactivity of pharmaceuticals poses a particular threat to aquatic
communities in combination with other exisiting threats to aquatic communities such as habitat
loss and other anthropogenic watershed disturbances.159–162 The stability of pharamceuticals in

43

the environment and their consistent presence all but guarantees sublethal effects among nontarget organisms in wastewater effluent impacted streams and raises the question of whether
molecular interactions and sublethal impacts resulting from pharmaceutical mixtures may
eventually lead to adverse effects at an organismal or population level. As the ToxCast assay
library has expanded, an increasing number of endpoints are designed to target specific
biological pathways known to be impacted by contaminant exposures. ToxCast assays screen
chemicals over a series of concentrations and are highly standardized in design and execution
such that direct comparisons across chemicals and assays are possible. A chemical is considered
“active” in a particular assay if the dose-response curve best fits a hill or gain-loss model over a
constant model.
Concentrations of pharmaceuticals and other contaminants analyzed in Muddy Creek
water samples were compared to bioactivity data in version 3.2 of the ToxCast database163
using the open-source R package toxEval (v.1.2.0)164 guided by previously published
parameters.165,166 The biological importance of detected chemicals is established through the
use of exposure-activity ratio (EAR) values, which relate the measured concentration of a
chemical in a sample to the concentration at which a threshold of bioactivity response is
reached in a given ToxCast assay (Equation 1). A ratio greater than one indicates that the
measured concentration of a chemical exceeded the threshold at which biological effects were
detected in a particular assay. The threshold used to establish assay activity was activity
concentration at cutoff (ACC), which is the concentration at which a dose response curve rises
above background level.167
!"#$%&'( *+,-.-,/ 01,-$ (!*0) =

!"#$%&"' )*+). *- ./" )/"!0)#1 (34)
677 *- ./" )/"!0)#18#$$#9 "+':*0+. (34)
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(1)

The ACC is an assay-specific threshold determined from a multiplier of median absolute
deviation of activity across all chemicals tested within the assay. Metrics like half-maximal
concentration (AC50) can also be used to generate EAR values; however, the advantage of ACC
is that it normalizes variation in chemical potency as the activity cutoff point is determined
relative to all chemicals tested in a given assay.168
Assay endpoints with common biological targets or within the same AOP are presumed
to have additive effects169 and thus EAR values can be summed to represent integrated risk
across multiple chemicals. EAR values were grouped and summed in different ways to address
specific questions about the aggregated effects (Equation 2). To assess the relative biological
importance of the different chemicals measured in Muddy Creek, individual assay-chemical EAR
values were grouped and summed by chemical. To predict likelihood of molecular effects within
specific biological pathways from exposure to all chemicals in a sampling event, EAR values
were grouped and summed by the gene or biological targets of assay as has been done
previously.170–174 ToxCast EAR values used in this way are analogous to and have demonstrated
consistenency with traditional in vivo toxicity quotients (TQ) generated from existing waterquality benchmarks.166 A chemical prioritization study of contaminants in Great Lakes
tributaries demonstrated consistency between a TQ of 0.01 and EAR of 0.001 when used as a
threshold for establishing probable effects.166 Thus, an EAR of 0.001 was used as an effects
threshold in this study.
!*0;&*%: = ∑!*0[#11 #$$#9 "+':*0+.$ &"1"=#+. .* ./" ;&*%:]

(2)

As pharmaceuticals are often tested in ToxCast as chemical salts formulations but
quantified in the environment in their non-ionic forms, input CASRNs were adjusted to reflect
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salt formulations if a non-ionic form was unavailable or had less assay coverage. Of the 67
pharmaceuticals detected over the sampling period, 49 had assay data available as either a free
compound (15) or salt (34), of which 20 only had data available in salt form and 14 had greater
assay coverage. Table B.1 lists pharmaceuticals formulations used in the ToxCast analysis that
differed from those measured analytically in stream water samples. As described in Blackwell
2017, non-ionic and salt forms were considered equipotent for the purposes of EAR generation
and the molecular weights used to calculate ACC values (μM) reflect measured compounds.167
Of the 1473 assays in the ToxCast database, 449 were available for the chemicals
measured in the study. Many of the quality assurance considerations described in prior
studies165,167,175 to eliminate non-specific and irrelevant endpoints and unreliable doseresponse curves were also used in this study. Quality control flags are used within the ToxCast
database to identify unreliable dose-response curves and false-positive results. Assay-chemical
pairs were excluded from consideration if any one of the following quality control flags was
assigned: “Borderline active”, “Only highest conc above baseline, active”, “Gain AC50 < lowest
conc & loss AC50 < mean conc”, and “Biochemical assay with < 50% efficacy”. Assays reporting
in the “loss” direction from the Attagene platform and “gain” direction from the NovaScreen
platform were also removed from consideration as these assays were not designed or
optimized for those signal directions. All remaining assay-endpoint curves contributing to EAR
values>0.001 were manually inspected to ensure that only reliable dose-response curves were
considered ACC value determination. All exclusions are summarized in Table B.2.
A final curated selection of 276 assays were considered for determining EAR values for
the 49 detected chemicals with ToxCast assay coverage, which resulted in 955 unique chemical-
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assay combinations. Assays used for EAR determination monitored some of the following
bioeffects and targets: cytotoxicity (75), steroidal and non-steroidal nuclear receptors (40),
rhodopsin-like receptors (38), DNA binding (27), ctyochrome activity (16), ion channel activity
(7) and steroid hormone acticivity (5). The median number used to screen each chemical was
eight and ranged from one assay for 11 chemicals to 78 assays used to screen the anithistamine
loratadine.
3.3

Results and Discussion

3.3.1 ToxCast predicts bioeffects that capture a narrow set of pharmaceuticals with some
seasonal and spatial variation within the stream.
Although nearly half of the 49 chemicals with ToxCast assay coverage generated EAR
values that exceeded the 0.001 threshold for biological relevance, a smaller set of chemicals
was responsible for the most relevant bioeffects predicted by ToxCast assays (Table B.3). When
individual chemical-assay EAR values were summed by chemical (EARchem), 24 of the 49
chemicals with ToxCast assay coverage generated EARchem values above 0.001, and 18 chemicals
generated individual chemical-assay EAR values above 0.001 (Table B.3). Assays contributing to
EARchem values above 0.001 evaluated biological targets relevant to some specific biological
pathways, such as those containing steroidal nuclear receptors or G protein-coupled receptors,
and others with non-specific effects like DNA repair and cytotoxicity (Table B.3).
Chemicals responsible for predicted bioeffects most relevant to fish included
carbamazepine, diphenhydramine, and metformin, which all had EARchem values that exceeded
0.01 at the effluent and DS1 sites in every month examined (Figure 3.1). In all months except
for April, carbamazepine EAR values exceeded 0.1 at the effluent and DS1 sites. The maximum
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EARchem values (ranging from 0.042 to 0.25) at the effluent, DS1 and DS2 sites in all months
excpet April and May were generated by carbamazepine. Carbamazepine is an anticonvulsant
known to be persistent in the environment and did not differ substantially between month or
between stream sites (Effluent, DS1, and DS2). On the other hand, diphenhydramine, a firstgeneration antihistamine did exhibit variation by stream site and month with the highest
concentrations observed at the effluent and DS1 sites during sampling events in April and May,
months that mark spring allergy season in Iowa. Diphenhydramine frequently went undetected
at the DS2 site (5 km below the WWTP effluent outfall) but consistently detected in the
approximate range of 50-200 ng/L at the effluent and DS1 sites (Figure B.4). Chlorpheniramine,
omeprazole, and thiabendazole also had bioeffects predicted with EARchem values above 0.01 at
the effluent site in at least four of the seven months analyzed.
Many of the chemicals detected at highest concentrations in the months analyzed were
not among those with high EARchem values. Notably missing were relevant endpoints for the ten
antidepressants and degradates surveyed in Muddy Creek, some of which occurred at levels
known to cause behavioral changes in fish including venlafaxine125,176 and bupropion.177
Venlafaxine did have two EARchem hits above 0.001 at the effluent sites in January and May, but
they were the result of non-specific endpoints (cytotoxicity as measured by the “Tox21 RT
HEPG2 GLO” assay series) (Figure 3.1). Several pharmaceuticals and degradates (fexofenadine,
guanylurea, gabapentin, sulfamethoxazole, and tramadol) were consistently detected at
concentrations above 100 ng/L at the effluent, DS1, and DS2 sites in the months examined but
have not yet been screened in any ToxCast assays (Figure B.3)
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Figure 3.1. Exposure activity ratio (EAR) values for each chemical-assay endpoint are summed by chemical to
produce the EARchem values shown below for the 49 pharmaceuticals and other CECs detected at each stream site in
monthly sampling events (January 2018 – August 2018, excluding March). Individual exposure-activity ratios are
calculated as the quotient of the measured concentration of each chemical in a sampling event divided by activity
concentration at cutoff (ACC) for a specific assay.

Assessing EAR values grouped and summed by common gene and biological targets
instead of by chemical provides a way to compare predicted biological pathway effects to those
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observed experimentally through gene expression. Over the seven months examined, 20 assay
gene targets that had at least two instances of EARgene values above 0.001 (Table 3.2, Figure
3.1). The androgen receptor (AR) was the target of the top EARgene, which was aggregated from
EAR values of four chemicals with bioactivity in four distinct AR agonism assays. However, in all
instances, carbamazepine contributed to the bulk of EARgene value for AR. Diphenhydramine
was the only chemical that contributed to EARgene values for the H1 histamine receptor gene
(HRH1) despite the presence of other chemicals with the same mechanisms of action.
Chlorpheniramine, another a first-generation antihistamine designed to target the H1 histamine
receptors, has not been screened against any histamine assays in ToxCast.
Table 3.2. ToxCast assay gene targets and chemical mixtures that generated EAR values greater than 0.001 when
grouped and summed by gene target are shown below. Shaded months indicate the presence of at least one site
with ΣEARgene >0.001. Maximum ΣEARgene values noted in the month in which the maximum EAR value occurred.
*Fluticasone only contributed to ΣEARgene mixtures for AR and NR3C1 in May.
Gene

Chemicals

Jan

Feb

Apr

AR
HRH1

Carbamazepine, Ranitidine, Metformin, Fluticasone* 0.29
Diphenhydramine

FOS|JUN

Caffeine

NR3C1

Metformin, Fluticasone*

CYP1A1
SOX1

Thiabendazole
Caffeine

0.0059

CYP1A2

Thiabendazole

0.0056

OPRM1

Methadone

CHRM3

Diphenhydramine

CHRM5

Diphenhydramine

TSHR

Albuterol

SLC6A4

Methadone

PPP2CA

Thiabendazole

CHRM1

Diphenhydramine

0.0019

CHRM2

Diphenhydramine

0.0016

CYP2C19

Diphenhydramine

CHRM4

Diphenhydramine

PDE4A

Atrazine

HTR2C

Diphenhydramine

May

Jun

Jul

Aug

0.21
0.038
0.024

0.010

0.0052
0.0030
0.0026
0.0025
0.0022
0.0020

0.0015
0.0014
0.0014
0.0014
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Figure 3.2. Exposure activity ratios of chemical-assay endpoints summed by gene target (ΣEARgene) in each month
and site.

3.3.2 Contextualizing the high EAR values of carbamazepine and diphenhydramine.
The two primary chemical and gene targets prioritized in the ToxCast analysis already
have well-documented ecotoxicological impacts, particularly with respect to fish. The adverse
effects of carbamazepine on the male reproductive system that are well known in mammals178–
181

have also been reported in fish. In Danio rerio, chronic (6-week) carbamazepine exposure at

0.5 μg/L decreased reproductive success and 11-ketotestosterone (KT) plasma levels in both
male and females, and increased mortality among directly exposed embryos.176,182 Paternal
exposure to carbamazepine 10 μg/L led to transgenerational impairments in reproductive
behaviors and success.183 Carbamazepine functions as voltage-gated sodium channel blocker is
prescribed to treat seizures, neuropathic pain, and bipolar II.184 Although the mechanism
through which carbamazepine disrupts 11-ketotestosterone production and lowers
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reproductive capacity is unclear, and it is possible that reducing the excitability of neurons (by
maintaining voltage gated sodium channels in their inactive state) may also decrease the
neuronal stimulation needed for steroid hormone synthesis and normal reproductive organ
function.185 In Danio rerio, chronic (6-week) exposures to carbamazepine at 0.5 μg/L decreased
reproductive success and 11-ketotestosterone (KT) plasma levels in both males and females
and increased mortality among directly exposed embryos.176,182 Paternal exposure to
carbamazepine at 10 μg/L led to transgenerational impairments in fecundity and behaviors
related to reproductive success.183,186 Exposure to 1 μg/L upregulated AR transcription in
female medaka (Oryzias latipes).187 A 28-day exposure to carbamazepine in gilthead sea bream
(Sparus aurata) generated significant enrichment of androgen and estrogen metabolism
pathways.188
Diphenhydramine is a first generation H1 antihistamine with several mechanisms of
action relevant to ecotoxicity. In competing with histamine to bind to H1 receptors in smooth
muscle cells, it prevents the vascular dilation that causes swelling and redness associated with
allergic reactions.189 More recently, recently diphenhydramine has been shown to reduce
allergic response not just by competitively blocking HRH1 but also by inhibiting production of
histamine in the first place by downregulating the rate limiting enzyme that synthesizes
histamine, histidine decarboxylase (HDC).190 Diphenhydramine crosses the blood-brain barrier
allowing it to target the 5H-T (serotonin) reuptake transporter (SERT),191 which is the source of
its sedative effects, and the muscarinic acetylcholinesterase receptor, which it competitively
antagonizes.
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The LC50 of diphenhydramine is high in fish (692 mg/L for 3 dpf zebrafish and 262 for 6
dpf),189 and as a result antihistamines are often considered to pose low risk to aquatic
vertebrates. However, sublethal impacts on behavior have been documented at much lower
concentrations of diphenhydramine, possibly owing to its inhibition of serotonin reuptake.191
For example, an LOEC of 5.6 μg/L was established for reduced feeding rate in fathead minnows
(Promelas pimephales).192 More recently, the histaminergic system has drawn attention for the
role it plays in modulating aggression and other behaviors important in establishing social
hierarchies in zebrafish.193,194 Histidine decarboxylase (hdc) was shown to be upregulated in
dominant zebrafish, along with histamine receptors hrh1 and hrh2.195 Elevated hdc expression
was maintained in adult offspring of dominant (male and female) zebrafish pairings in a
transgenerational study that identified inherited dominant and subordinate behaviors.194 In
addition to the production of histamine for allergic responses, hdc also plays a role during
embryonic brain development where histamine regulates the number of hypocretin/orexin
neurons that are hypothesized to eventually regulate the number of mast cells producing
histamine in adults.196 The expression of hdc in larval zebrafish thus may contribute to the
plasticity of the histaminergic system in the brain later in adulthood. Finally, the histamine/H1
receptor axis is now also recently known to play an essential role during cardiac development in
larval zebrafish in promoting cardiomyocyte differentiation through activation of the ERK 1/2STAT3 pathway.197
3.3.2 In vivo data aligns with some ToxCast bioeffect predictions.
In vivo exposures capture some molecular and pathway-based impacts predicted by
ToxCast assay data, such as impacts to the histaminergic system and some biomarkers of
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cardiovascular impacts. Although most protein targets in ToxCast are likely conserved across all
vertebrate species,198 ToxCast assays were primarily designed to target mammalian
endpoints.146 Thus, many exposure bioeffects relevant to zebrafish development are not
screened in existing ToxCast assays, including the visual system, metabolic, and musculoskeletal
impacts observed in the January and May embryo exposures (Chapter 2).
Diphenhydramine generated EARgene values for the HRH1 gene target of 0.17 and 0.12 at
the effluent and DS1 sites in May and 0.12 and 0.09 at the effluent and DS1 sites in January.
While the HRH1 gene was not detected in RNA sequencing of zebrafish larvae in Chapter 2,
histidine metabolism was statistically overrepresented at the effluent site in the 6 dpf May
exposure. Notably, there was a -4 log2 fold change (p<0.01) in hdc expression at both the
effluent and DS1 sites in May (at both 3 and 6 dpf) but no significant differential expression of
the gene in January (Figure 3.3). Diphenhydramine was the only antihistamine detected with
the ability to downregulate hdc expression.190 Diphenhydramine concentrations at the effluent
and DS1 sites were 113 and 81 ng/L in January and 150 and 109 ng/L in May (Figure B.4).
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Figure 3.3. Gene expression from RNA-sequencing of 6 dpf larval zebrafish exposed to water from the May effluent site. Log2
fold changes relative to the US1 site are shown on the KEGG pathway for histidine metabolism (dre00340).107 Ovals indicate
metabolites and rectangles indicate genes. Pathway rendered by Pathview.199

Of all assay gene targets with EAR values>0.001 in January and May, eight had
significant differential expression in RNA sequencing of larval zebrafish exposures: AR, SLC6A4A,
OPRM1, PPP2CA, CYP1A, NR3C1, CHRM4A, CHRM2A, and PDE4A. The two targets with the
greatest EAR values when summed by gene target were the androgen receptor (AR) and the
glucocorticoid receptor (NR3C1), both of which are on the gonadotropin releasing hormone
receptor pathways (Panther Pathway, P06664). The three chemicals identified in ToxCast assays
contributing to these EARs were ranitidine, metformin, and fluticasone; however, fluticasone
was only quantified above detection limit in May (0.32 ng/L at effluent). NR3C1 was not
differentially expressed in the two exposure months used for RNA sequencing, but AR was
significantly upregulated in the 3 dpf May comparisons between US1 and effluent (log2 fold
change 1.28, adjusted p-value<0.01) and between US1 and DS1 (log2 fold change 1.39, p<0.01).
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However, the androgen receptor was not detected in January exposures there was little
evidence of systematic impacts to hormone and reproductive pathways in either month.
The phosphatase 2a catalytic unit (PPP2CA) and the cholinergic receptor muscarinic 2
(CHRM2) are both involved in cardiovascular processes. The antifungal agent, thiabendazole,
generated significant bioactivity in an assay targeting PPP2CA, a gene involved in several
biological pathways including the KEGG pathway, “Adrenergic signaling in cardiomyocytes,”
with EAR values of 0.002 and 0.001 at the effluent site in January and May respectively.
Although “Adrenergic signaling in cardiomyocytes” was only overrepresented among
differentially expressed transcripts in the May exposures (Figure 2.3), the zebrafish ortholog
ppp2ca was significantly dysregulated at the effluent site in the 6 dpf exposures of both months
(log2 fold changes of 5.0 in May and -4.7 in January, p-value<0.05). In an assay targeting
CHRM2, diphenhydramine generated EAR values of 0.001 at the effluent site in both January
and May. In zebrafish, chrm2a plays a role in the development of the cardiac conduction system
and regulation of heart rate. Chrm2a was significantly upregulated at the effluent and DS1 sites
in the May 3 and 6 dpf exposures with log2 fold changes ranging from 3.6 to 4.6 (p-value<0.01)
and was significantly downregulated at DS1 in the January 3 dpf exposure (log2 fold change -2.6,
p-value<0.05).
Targeted gene expression was used to quantify expression of select genes differentially
expressed in RNA sequencing and other common wastewater biomarkers in zebrafish across
seven monthly exposures between January-August 2018 (excluding March). Transcript
abundance measurements from the NanoString platform were also used to validate differential
expression in RNA sequencing from Chapter 2. Eight genes differentially expressed at the
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Effluent and DS1 sites in May and January were also significant in RNA sequencing and fold
changes between the two platforms were comparable (R2 = 0.82) (Figure A.6). Of the 46 genes
targeted by the NanoString CodeSet, 21 were differentially expressed in comparisons of the
effluent, DS1, or DS2 sites to the upstream reference (US1) (|log2 fold change|>0.75, p<0.05)
(Figure 3.4). Genes with significant differential expression targeted pathways related to steroid
hormones, brain and eye development, lipid and glucose metabolism, circadian rhythm, and
xenobiotic response. Genes related to circadian rhythm (per1b, cry2, cry5) were differentially
expressed at DS1 and DS2 in January, May, and June. Genes with neurological and visual system
functions were upregulated at DS2 in January (gngt2b, gngt1, gabra1) and downregulated at the
effluent site in May (gnat2, gngt2b). Pck1 plays a role in glucose metabolism and was
downregulated in April (DS2) and June (all sites) but upregulated in May (DS1, DS2).
Genes with functions related to steroid hormones and reproductive processes were
upregulated at DS2 in January (cyp19a1b, cyp17a, hsd17b1, hsd3b2, and vtg), upregulated at
DS2 in February (cyp17a), and upregulated at the effluent and DS1 sites in April (vtg1, cyp17a).
The lack of differential expression in these reproduction related genes at the effluent site is
notable. One technical factor was that several of these genes were expressed at levels close to
the limit of detection at the effluent site and thus could not be reliably quantified.
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Figure 5.4. Log2 fold changes (vs. US1 reference) of all genes with significant (B-H adjusted p-value<0.01)
upregulation (red) and downregulation (green) relative to the US1 reference site.

3.4

Environmental implications.
The prioritization of pharmaceuticals and other CECs that exist in complex chemical

mixtures in wastewater effluent-dominated surface water is a challenge. Traditional
ecotoxicological endpoints such as mortality and gross deformities may drastically
underestimate exposure risks in fish as they do not capture the neurological impacts and other
sublethal impacts of pharmaceutical exposure that may alter feeding and reproductive
behavior.200 The EAR approach to leveraging environmental chemical data against the chemicalassay dose-response curves in the ToxCast database can identify and aggregate potential
molecular bioeffects to generate predictions about sublethal impacts that may be relevant to
aquatic species.
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Sublethal molecular and biological pathway impacts predicted by ToxCast assay data
identified carbamazepine and diphenhydramine individually as likely to cause molecular
impacts with respect to androgen and H1 histamine receptors. The overrepresentation of the
histidine metabolism KEGG pathway and downregulation of hdc in May was consistent with
ToxCast predictions. While the histaminergic system in zebrafish allows for substantial brain
plasticity, the potential impacts of suppressed hdc expression during early development on
aggression and social behavior in adulthood should be further explored. Mixtures of chemicals
with AR activity (carbamazepine, metformin, ranitidine, and fluticasone) were predicted to
effect reproductive pathways, but gene and pathway-based biomarkers of endocrine disruption
were not evident in global and targeted gene expression of zebrafish larvae. However, many of
these genes are expressed at very low levels during larval development. While it is possible that
biologically relevant changes in gene expression occurred below the detection limit in both RNA
sequencing and NanoString, it is also possible that the impact of some endocrine disruptors
may depend on stage of development and could impact pathways outside those associated
directly with reproduction.
Enormous complexity is involved in assessing the risk of biological effects from exposure
to complex chemical mixtures in wastewater effluent. Contaminants found in wastewater
effluent, including pharmaceuticals, pesticides, and other chemicals with designed bioactivity,
can alter gene expression and disrupt cellular functions at very low exposure concentrations,
but the associated risk of those impacts ultimately depends on whether they lead to adverse
effects within individuals. The AOP framework has proven invaluable to the task of integrating
knowledge from the ToxCast database with ‘omics and phenotype data to establish the
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relevance of early biochemical responses to chemical exposures.201 However, the utility of
ToxCast bioeffects predictions in aquatic ecotoxicology is inherently limited by the coverage of
biological pathways and biological functions within the ToxCast library. While the conservation
of biological pathways relevant to both human health and other vertebrates is substantial,
effluent-dominated streams continuously expose fish to contaminant mixtures, which may
result in exposure scenarios less relevant to human health such as continuous exposure during
early development via membranes and digestive system and eventually through gills. The
ToxCast library would be improved by the addition of assay endpoints specific to fish (such as
vitellogenin induction), and the addition of essay endpoints with high specificity to mechanisms
of action in common pharmaceutical and CECs. Greater coverage of pharmaceuticals within
existing assays is also necessary. Currently, the only endpoints specific to fish in the ToxCast
database are from in vivo HTS assays from the Tanguay lab that assess developmental
morphology in zebrafish embryos.202 However, recently, HTS assays with behavioral endpoints
in embryonic and larval zebrafish have demonstrated higher sensitivity compared to
morphological endpoints.95,203 Incorporating these and other behavioral assays into ToxCast
would likely capture lower effect levels relevant to the neurological effects of exposure to
pharmaceuticals and CECs.
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Chapter 4: Conclusions and Future Research
The goal of this thesis was to identify potential gene and pathway-based biomarkers of
exposure to an effluent-dominated stream in zebrafish larvae as they relate to changes in the
chemical composition of the stream over space (above and below the effluent outfall) and time
(seven monthly sampling events). The 3 and 6 dpf exposures of larval zebrafish to January and
May water samples (Chapter 2) revealed transcriptomic signatures that differed by
developmental stage and by chemical composition of sampling sites and months. Although
biological processes related to heart development were overrepresented in both months, the
effect was more pronounced in May, particularly with respect to the 3 dpf exposures. In the
May 6 dpf exposures, histidine metabolism was overrepresented, suggesting the influence of
antihistamines which were detected at higher concentrations in May compared to January.
Visual and neurological development processes were also overrepresented in May and not
January, which may relate to the higher total concentration of antidepressants in May.
In Chapter 3, ToxCast in vitro assay data was leveraged against chemical data from the
same seven monthly water samples used for zebrafish exposures. Both ToxCast and global gene
expression identified impacts within the histaminergic system that were unique to, or more
pronounced in May compared to January. Impacts to cardiac functioning were also suggested in
both analyses. Biological Processes and KEGG pathways related to the cardiovascular system
were overrepresented among DETs in both exposure months, and two ToxCast assay gene
targets involved in cardiac functioning (PPP2CA and CHRM2) that generated EAR values above
the 0.001 were significantly dysregulated in both January and May zebrafish embryo exposures.
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Many of the pharmaceuticals found at the highest concentrations in each month (fexofenadine,
venlafaxine, gabapentin, sulfamethoxazole, metoprolol, acyclovir, lidocaine, and tramadol), did
not contribute substantially to bioeffects predictions. Rather a select few chemicals targeting
steroid pathways (carbamazepine and metformin) and the H1 histamine receptor
(diphenhydramine) were responsible for the most prominent bioeffects.
The use of the US1 site as a baseline reference for establishing gene expression changes
related to detected contaminants normalized differential gene expression against the
background water chemistry of the stream. However, In Chapter 2, the high estrogenicity
measured at US1 in May and but not at US1 in January suggests the possibility of consequential
chemical inputs not detected in the USGS chemical analysis. Despite the high estrogenicity at
US1 in May, commonly used biomarkers of endocrine disruption were not detected in either
NanoString or RNA-sequencing. Neither was there evidence of systematic overrepresentation
of reproductive pathways among differentially expressed transcripts in RNA-sequencing.
This thesis was motivated by the need to expand the range of biological impacts
currently monitored in aquatic ecosystems contaminated with complex mixtures of bioactive
chemicals from wastewater effluent. While traditional ecotoxicological endpoints for fish
provide important information about growth, reproduction, and acute toxicity, molecular
sublethal impacts related to specific biological pathways can provide more sensitive and
granular endpoints. Both HTS in vitro assay data and global and targeted gene expression were
used to identify potential impacts of exposure on zebrafish larvae. The resulting associations
between chemical composition, ToxCast predicted bioeffects, and changes in gene expression
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from zebrafish embryo exposures are exploratory in nature and suggest several directions for
future studies.

(1) Lab-based exposures are needed to the test the associations observed in this thesis
between chemicals prioritized by ToxCast assay data and the bioeffects observed in
larval zebrafish exposures. Specific relationships to investigate include the effects of
diphenhydramine on histidine metabolism and the effects of thiabendazole and
diphenhydramine on cardiovascular development.
(2) Many pharmaceuticals detected at high concentrations in WWTP effluent have either
not been screened by many ToxCast assays or haven’t been screened at all.
Pharmaceuticals and degradates that are consistently detected in effluent-dominated
surface water at high concentrations (e.g., fexofenadine, metformin, and venlafaxine)
should be prioritized for testing within ToxCast regardless of whether their
pharmacokinetic properties low risk to aquatic organisms. The constant presence of
such pharmaceuticals may expose species throughout development and adulthood. In
these cases, transcriptomics and other ‘omics strategies could be used to identify
potential off-target biological impacts at multiple life stages.
(3) Investigation is needed to characterize the ways endocrine disruption manifests during
embryonic and larval zebrafish development. Many pharmaceuticals indirectly target
endocrine system pathways and have the potential to alter reproductive functioning in
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adult fish. However, little is known about how exposure to pharmaceuticals that
indirectly target the endocrine system alter other pathways during development.

(4) To improve ability to predict bioeffects from CEC mixture composition in aquatic
environments, analyses are needed that correlate water chemistry parameters and
chemical composition to transcriptomic and other ‘omics data.
While ToxCast and other “systems toxicology” approaches to predictive toxicity offer
much needed tools for assessing mixture toxicity of emerging contaminants, these tools can
only predict the effects they were designed to evaluate and are only as reliable the data that
supports them. As is the case with data from all targeted analyses in environmental chemistry
and toxicology, the bioeffects predictions generated from ToxCast assays represent “the tip of
the iceberg” with respect to what aquatic organisms likely experience. The lack of specificity to
aquatic organisms within ToxCast assays and the low assay coverage for top pharmaceutical
contaminants makes the integration of in vivo bioeffects data with in vitro predictions even
more important.
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METHODS
Bioluminescent Yeast Estrogenicity Screen (BLYES). 20 µL of sample extract was added in
triplicate to the wells of white, solid-bottom 96-well microtiter plates and evaporated at room
temperature in a Class II biological safety cabinet. Following evaporation, 200 µL of a 48-hour
culture of strain BLYES adjusted to 0.4 (OD600) in fresh yeast minimal media (YMM eu–, ura–) was
added to each well. A 12-point standard curve of 17β-estradiol (E2; Sigma-Aldrich Co.) was
included on each plate. A media control was included on all plates to establish background
luminescence. Plates were covered and incubated in the dark at 30 °C for 4 hours. Luminescence
was quantified using a SpectraMax M4 microplate reader (Molecular Devices) in luminescence
mode (1,000 millisecond integration time), and estrogen equivalents (E2Eq) of each sample were
determined via interpolation to a 4-parameter curve within SoftMax Pro 6.2.2 (Molecular
Devices). Relative net agonistic activity per liter of sample was then calculated on the basis of
sample concentration. The detection limit for this assay was 0.18 ng/L E2Eq(BLYES).
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Figure A.1. Established USGS field sites along Muddy Creek in Coralville, IA, USA.

Figure A.2. Photos of each site taken by the authors on sampling days: January 8, 2018 and May
1, 2018.
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Figure A.3. Muddy Creek chemical detections (ng L-1) in January and May 2018 at US1 (100 m
above WWTP effluent outfall, 05454050), effluent (05454051), and DS1 (100 m below the
effluent outfall, 05454052). “E” indicates estimated measurement.111
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Figure A.6. KEGG pathways107 enriched (adjusted p-value <0.05) among transcripts differentially
expressed (DETs) (adjusted p-value <0.01, |log2 fold change| >1) between the effluent and US1
site in the May 3 dpf exposure: (A) Phototransduction and (B) Adrenergic signaling in
cardiomyocytes KEGG pathway. KEGG pathway diagrams rendered via pathview v1.30.1 (R
v4.0.1).204 Color scale reflects DET log2 fold change.
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Figure A.5. DETs from January and May 3 dpf exposures on two enriched KEGG pathways: (1)
Cardiac muscle contraction and (2) Adrenergic signaling in cardiomyocytes. Pathways were
enriched (BH-adjusted p-value<0.05) among 3 dpf DETs at the effluent site (vs. US1) that were
upregulated in January and downregulated in May.
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NanoString

RNAseq

gene

month

site

0.8009611 2.610751

pck1

May

DS1

0.87886611 1.028346

fosab

Jan

DS1

1.63043612 1.318888

cyp1a

Jan

EFF

-2.1902871

-2.00028

fosab

May

DS1

-0.8334811

-0.46597

pparaa

May

DS1

-1.5214687

-1.61133

fosab

May

EFF

-0.9062394

-1.18363

gnat2

May

EFF

-0.9205855

-1.49584

gngt2b

May

EFF

Figure A.6. Regression of log2 fold changes on the RNA sequencing and NanoString platforms.
Genes validated are listed in the table above.
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Table A1. Reporting limits from methods used in the 2017-2018 pharmaceutical study at Muddy Creek in North Liberty and Coralville,
Iowa. Samples were analyzed at the National Water Quality Lab using LC-MS/MS as described by Furlong et. al. 2014.98 Table adapted
from Meppelink et al., 2020.111
Parameter name
1,7-Dimethylxanthine

Parameter
CAS
code
number
67446 611-59-6

10-Hydroxy-amitriptyline

67995 64520-05-4

Abacavir

68022 136470-78-5

Acetaminophen

Reporting
level
88 ng/L

Source, use
Stimulant, metabolite of caffeine

8.3 ng/L

Degradate of amitriptyline

87

2 ng/L

Antiviral; reverse transcriptase inhibitor

67436 103-90-2

20 ng/L

Over-the-counter analgesic, antipyretic

Acyclovir

67484 59277-89-3

22 ng/L

Antiviral for treatment of herpes simplex

Albuterol

67437 18559-94-9

6.7 ng/L

Beta2-adrenergic receptor agonist for asthma treatment

Alprazolam

68250 28981-97-7

21 ng/L

Benzodiazepine used to treat anxiety disorders

Amitriptyline

67522 50-48-6

37 ng/L

Tricyclic antidepressant

Amphetamine

67461 300-62-9

4.4 ng/L

Psychostimulant

Antipyrine

67477 60-80-0

50 ng/L

Prescription analgesic, antipyretic

Atenolol

67502 29122-68-7

13 ng/L

Beta blocker used for treatment of hypertension

Atrazine

65065 1912-24-9

20 ng/L

Herbicide; used in this method to compare performance between compounds and between methods

Benztropine

67997 86-13-5

44 ng/L

Anticholinergic used in treatment of Parkinson's disease

Betamethasone

67485 378-44-9

114 ng/L

Bupropion

67439 34911-55-2

18 ng/L

Antidepressant and smoking cessation aid

Caffeine

67440 58-08-2

91 ng/L

Psychoactive stimulant in coffee, tea, and other preparations

Carbamazepine

67441 298-46-4

11 ng/L

Anticonvulsant and mood stabilizer used for epilepsy, bipolar disorder, trigeminal neuralgia

Carisoprodol

67498 78-44-4

20 ng/L

Muscle relaxant

Synthetic glucocorticoid steroid used to treat inflammatory and autoimmune conditions

Parameter name
Chlorpheniramine

Parameter
CAS
code
number
67497 132-22-9

Reporting
level
54 ng/L

Source, use
Over-the-counter antihistamine for relief of allergy symptoms

88

Cimetidine

67442 51481-61-9

140 ng/L

Histamine H2-receptor antagonist that inhibits production of stomach acid

Citalopram

67505 59729-33-8

6.6 ng/L

Selective serotonin reuptake inhibitor (SSRI) used to treat major depression, anxiety disorders

Clonidine

67518 4205-90-7

61 ng/L

Antihypertensive

Codeine

67443 76-57-3

32 ng/L

Opiate used as analgesic, antitussive, and antidiarrheal

Cotinine

67444 486-56-6

6.4 ng/L

Metabolite of nicotine; tobacco constituent

Dehydronifedipine

67445 67035-22-7

20 ng/L

Metabolite of the antihypertensive nifedipine

Desmethyldiltiazem

67999 --

70 ng/L

Degradate of diltiazem

Desvenlafaxine

68251 93413-62-8

84 ng/L

Dextromethorphan

67468 125-71-3

8.2 ng/L

Antidepressant serotonin-norepinephrine reuptake inhibitor, also major active metabolite of
venlafaxine
Cough suppressant in over-the-counter cold and cough medications

Diazepam (valium)

67499 439-14-5

4 ng/L

Diltiazem

67519 42399-41-7

10 ng/L

Calcium channel blocker used to treat hypertension, angina, some arrhythmias

Diphenhydramine

67447 147-24-0

48 ng/L

Antihistamine

Duloxetine

67448 116539-59-4

37 ng/L

Antidepressant; serotonin and norepinephrine reuptake inhibitor

Erythromycin

67449 114-07-8

80 ng/L

Macrolide antibiotic

Ezetimibe

67487 163222-33-1

205 ng/L

Fadrozole

68012 102676-47-1

13 ng/L

Aromatase inhibitor used for treatment of breast cancer

Famotidine

68000 76824-35-6

34 ng/L

Histamine H2-receptor antagonist that inhibits production of stomach acid

Fenofibrate

67489 49562-28-9

6.4 ng/L

Fibrate drug used to reduce cholesterol levels

Fexofenadine

67510 83799-24-0

44 ng/L

Terfenadine degradate; an antihistamine used to treat allergies

Benzodiazepine used to treat anxiety, insomnia, seizures

Cholesterol-reducing medication

Parameter name

Parameter
CAS
code
number
67478 86386-73-4

Reporting
level
30 ng/L

Fluoxetine

67450 54910-89-3

26 ng/L

Selective serotonin reuptake inhibitor (SSRI) used to treat major depression, anxiety disorders

Fluticasone propionate

67529 80474-14-2

30 ng/L

Synthetic corticosteroid used to treat asthma and eosinophilic esophagitis

Fluvoxamine

67521 54739-18-3

80 ng/L

Selective serotonin reuptake inhibitor (SSRI) antidepressant used to treat depression, anxiety disorders

Gabapentin

52817 60142-96-3

160 ng/L

Glipizide

68001 29094-61-9

80 ng/L

Sulfonylurea antidiabetic drug

Glyburide

68002 10238-21-8

58 ng/L

Sulfonylurea antidiabetic drug

Guanylurea

52816 141-83-3

140 ng/L

Transformation product of Metformin

Hexamethylenetetramine

52815 100-97-0

110 ng/L

Used in the treatment of urinary tract infections

Hydrocodone

67506 125-29-1

40 ng/L

Hydrocortisone

67459 50-23-7

147 ng/L

Naturally-produced glucocorticoid hormone used for immunosuppressive and anti-inflammatory effects

Hydroxyzine

68005 68-88-2

7.4 ng/L

Antihistamine, sedative

Iminostilbene

67481 256-96-2

145 ng/L

Intermediate for manufacture of carbamazepine, tricyclic antidepressants, also degradate

Ketoconazole

68014 65277-42-1

113 ng/L

Antifungal

Lamivudine

68018 134678-17-4

16 ng/L

Lidocaine

67462 137-58-6

Loperamide

67515 53179-11-6

80 ng/L

Loratadine

67488 79794-75-5

7 ng/L

Lorazepam

67470 846-49-1

202 ng/L

Meprobamate

67464 57-53-4

12 ng/L

Fluconazole
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8 ng/L

Source, use
Triazole antifungal

Anticonvulsant and used to treat neuropathic pain

Semi-synthetic opioid, narcotic analgesic and antitussive

Reverse-transcriptase inhibitor used to treat Hepatitis-B
Topical anesthetic
Opioid antidiarrheal
Antihistamine
Benzodiazepine used for its anxiolytic, amnesic, sedative/hypnotic, anticonvulsant, and muscle relaxant
effects
Carbamate derivative used as an anxiolytic

Parameter name
Metaxalone

Parameter
CAS
code
number
67504 1665-48-1

Reporting
level
16 ng/L

Source, use
Muscle relaxant
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Metformin

67492 657-24-9

13 ng/L

Treatment of Type 2 diabetes

Methadone

67500 76-99-3

7.6 ng/L

Synthetic opioid used as an analgesic and to treat opioid addiction

Methocarbamol

67501 532-03-6

11 ng/L

Muscle relaxant

Methotrexate

67525 59-05-2

52 ng/L

Antimetabolite and antifolate drug used in treatment of cancer

Methyl-1H-benzotriazole

67514 29385-43-1

80 ng/L

Metoprolol

67523 51384-51-1

10 ng/L

Corrosion inhibitor; used in this method to compare performance between compounds and between
methods
Used to treat cardiovascular disease, especially hypertension

Morphine

67458 57-27-2

80 ng/L

Opiate used as analgesic

Nadalol

68006 42200-33-9

20 ng/L

Beta blocker used to reduce high blood pressure, migraine headaches, chest pain

Nevirapine

68017 129618-40-2

46 ng/L

Antiretroviral used to treat HIV-1 infection

Nicotine

67493 54-11-5

58 ng/L

Alkaloid stimulant found in tobacco

Nizatidine

67479 76963-41-2

80 ng/L

Acid inhibitor used to treat ulcer and acid reflux disease

Nordiazepam

68252 1088-11-5

20 ng/L

Norethindrone

67434 68-22-4

20 ng/L

Benzodiazepine drug used to treat anxiety; also active metabolite of diazepam and other
benzodiazepine drugs
Oral contraceptive component

Norfluoxetine

67451 56161-73-0

80 ng/L

Active metabolite of fluoxetine

Norsertraline

67532 87857-41-8

80 ng/L

Degradate of sertraline

Norverapamil

68007 67018-85-3

8.6 ng/L

Active metabolite of verapamil

Omeprazole +
Esomprazole
Oseltamivir

67512 -

16 ng/L

Proton pump inhibitors used to treat dyspepsia and ulcers

67511 196618-13-0

15 ng/L

Antiviral

Oxazepam

67469 604-75-1

226 ng/L

Benzodiazepine used to treat anxiety, insomnia, and alcohol withdrawal

Parameter name
Oxycodone

Parameter
CAS
code
number
67495 76-42-6

Reporting
level
25 ng/L

Source, use

91

Paroxetine

67527 61869-08-7

72 ng/L

Penciclovir

68021 39809-25-1

80 ng/L

Opiate used as analgesic and antidiarrheal; also compounded with acetaminophen or other antiinflammatory drugs such as ibuprofen
Selective serotonin reuptake inhibitor (SSRI) antidepressant used to treat depression, obsessivecompulsive disorder, panic disorder, anxiety disorders
Antiviral for treatment of herpes infections

Pentoxifylline

67480

9.4 ng/L

Cardiovascular drug that improves blood flow

Phenazopyridine

68008 94-78-0

13 ng/L

Used to treat pain, irritation in urinary tract

Phendimetrazine

67496 634-03-7

20 ng/L

Stimulant used as an appetite suppressant

Phenytoin

67466 57-41-0

188 ng/L

Piperonyl butoxide

67435 51-03-6

60 ng/L

Prednisolone

67483 50-24-8

150 ng/L

Prednisone

67467 53-03-2

105 ng/L

Pesticide synergist used in lice treatment medications; also used in this method to compare
performance between compounds and between methods
Corticosteroid drug used for the treatment of inflammatory and autoimmune conditions, also a
metabolite of prednisone
Synthetic corticosteroid immunosuppressant drug

Promethazine

67524 60-87-7

114 ng/L

Antihistamine, antiemetic, sedative

Propoxyphene

68009 469-62-5

28 ng/L

Opioid analgesic used for mild pain

Propranolol

67516 525-66-6

26 ng/L

Beta blocker used for treatment of hypertension, tremors

Pseudoephedrine +
Ephedrine
Quinine

67460 68011 130-95-0

80 ng/L

Antimalarial, bitter flavoring agent, mild antipyretic, and analgesic

Ractopamine

52814 97825-25-7

20 ng/L

Beta adrenoreceptor agonist growth promotant, used primarily in livestock

Raloxifene

67530 84449-90-1

80 ng/L

Selective estrogen receptor modulator prescribed for osteoporosis

Ranitidine

67452 66357-35-5

192 ng/L

Sertraline

67528 79617-96-2

16 ng/L

SSRI antidepressant used to treat depression, obsessive-compulsive disorder, anxiety disorders

Sitagliptin

67531 486460-32-6

97 ng/L

Antihyperglycemic

5/6/93

6 ng/L

Antiepileptic for seizures

Appetite suppressant, decongestant, stimulant

Acid inhibitor used to treat ulcer and acid reflux disease

Parameter name
Sulfadimethoxine

Parameter
CAS
code
number
67503 122-11-2

Reporting
level
30 ng/L

Source, use
Sulfonamide antibiotic drug
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Sulfamethizole

67476 144-82-1

104 ng/L

Sulfonamide antibiotic drug

Sulfamethoxazole

67454 723-46-6

20 ng/L

Sulfonamide antibiotic drug

Tamoxifen

68015 10540-29-1

Temazepam

67471 846-50-4

18 ng/L

Hypnotic

Theophylline

67494 58-55-9

80 ng/L

Antiasthmatic, diuretic

Thiabendazole

67455 148-79-8

4 ng/L

Parasiticide, fungicide

Tiotropium

67508 186691-13-4

50 ng/L

Bronchodilator used for chronic obstructive pulmonary disease

Tramadol

67517 27203-92-5

7.4 ng/L

Opiate used as analgesic

Triamterene

67475 396-01-0

5.2 ng/L

Diuretic

Trimethoprim

67456 738-70-5

20 ng/L

Antibiotic used in treatment of urinary tract infections

Valacyclovir

67507 124832-26-4

163 ng/L

Antiviral for treatment of herpes infections

Venlafaxine

67534 93413-69-5

5.2 ng/L

Antidepressant; serotonin and norepinephrine reuptake inhibitor

Verapamil

67472 52-53-9

140 ng/L

Calcium channel blocker used in the treatment of hypertension, angina pectoris, cardiac arrhythmia

Warfarin

67457 81-81-2

6 ng/L

270 ng/L

Estrogen receptor agonist used in the treatment of breast cancer

Anticoagulant, also used in rodenticides

Table A2. Field parameters for Muddy Creek, January and May 2018. Reprinted from Meppelink et al., 2020.
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month

site

Discharge,
instantaneous,
cubic feet per
second

Dissolved oxygen,
milligrams per liter

pH,
standard
units

Specific
conductance,
microseimens
per centimeter

Temperature,
degrees Celsius

Turbidity,
formazin
nephelometric
units (FNU)

Dissolved organic matter
fluorescence (fDOM),
micrograms per liter as
quinine sulfate equivalents
(QSE)

January

US1

0.38 *

9.2

7.4

1090

3.2

2.1

24.87

January

Effluent

3.22 *

9.1

7.6

3210

15.8

0.4

133.8

January

DS1

3.6 *

9.3

7.6

3000

14.3

1.5

124.6

January

DS2

1.22 *

11.6

7.8

2420

0

4.1

97.73

May

US1

0.71

7.7

7.6

889

13.9

14

40.34

May

Effluent

2.99

9.2

7.3

3040

14.9

May

DS1

3.7

9.1

7.5

2660

14.7

3.8

131.4

May

DS2

3.2

9

8

1890

13.8

4.5

89.59

153.8

* indicates value estimated by U.S. Geological Survey; the streamflow measurement for US1 for January was inadvertently deleted prior to formal documentation and was
estimated by using available streamflow measurements from the December 2017 (US1 and DS1) to January 2018 (DS1) and by comparing photos from December 2017 and January
2018 at US1.

Table A3. Chemical classes of detected chemicals in January and May 2018.
CAS
27203-92-5
103-90-2
78-44-4
137-58-6
76-99-3
532-03-6
76-57-3
76-42-6
68-88-2
1665-48-1
125-29-1
57-27-2
130-95-0
723-46-6
738-70-5
114-07-8
50-48-6
34911-55-2
59729-33-8
93413-62-8
54910-89-3
79617-96-2
93413-69-5
116539-59-4
148-79-8
86386-73-4
132-22-9
147-24-0
83799-24-0
79794-75-5
136470-78-5
59277-89-3
134678-17-4
196618-13-0
18559-94-9
58-55-9
29122-68-7
51384-51-1
525-66-6
42399-41-7
486460-32-6
396-01-0
52-53-9
81-81-2
29385-43-1
486-56-6
611-59-6
64520-05-4
86408-45-9
141-83-3
67018-85-3
56161-73-0
87857-41-8
657-24-9

Chemical classes
Chemical
Tramadol
Acetaminophen
Carisoprodol
Lidocaine
Methadone
Methocarbamol
Codeine
Oxycodone
Hydroxyzine
Metaxalone
Hydrocodone
Morphine
Quinine
Sulfamethoxazole
Trimethoprim
Erythromycin
Amitriptyline
Bupropion
Citalopram
Desvenlafaxine
Fluoxetine
Sertraline
Venlafaxine
Duloxetine
Thiabendazole
Fluconazole
Chlorpheniramine
Diphenhydramine
Fexofenadine
Loratadine
Abacavir
Acyclovir
Lamivudine
Oseltamivir
Albuterol
Theophylline
Atenolol
Metoprolol
Propranolol
Diltiazem
Sitagliptin
Triamterene
Verapamil
Warfarin
Methyl-1H-benzotriazole
Cotinine
1,7-Dimethylxanthine
10-Hydroxy-amitriptyline
Desmethyldiltiazem
Guanylurea
Norverapamil
Norfluoxetine
Norsertraline
Metformin
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Class
Analgesic-Antinflammatory
Analgesic-Antinflammatory
Analgesic-Antinflammatory
Analgesic-Antinflammatory
Analgesic-Antinflammatory
Analgesic-Antinflammatory
Analgesic-Antinflammatory
Analgesic-Antinflammatory
Analgesic-Antinflammatory
Analgesic-Antinflammatory
Analgesic-Antinflammatory
Analgesic-Antinflammatory
Anti-malarial
Antibiotic
Antibiotic
Antibiotic
Antidepressant
Antidepressant
Antidepressant
Antidepressant
Antidepressant
Antidepressant
Antidepressant
Antidepressant
Antifungal
Antifungal
Antihistamines
Antihistamines
Antihistamines
Antihistamines
Antiviral
Antiviral
Antiviral
Antiviral
Asthma Relief
Asthma Relief
Beta blocker
Beta blocker
Beta blocker
Cardiovascular Care
Cardiovascular Care
Cardiovascular Care
Cardiovascular Care
Cardiovascular Care
Corrosion inhibitor
Degradate
Degradate
Degradate
Degradate
Degradate
Degradate
Degradate
Degradate
Diabetes care

CAS
51481-61-9
76824-35-6
66357-35-5
1912-24-9
60142-96-3
57-53-4
298-46-4
57-41-0
28981-97-7
1088-11-5
439-14-5
54-11-5
125-71-3
73590-58-6
51-03-6
846-50-4
80474-14-2
58-08-2
300-62-9
50-98-6

Chemical classes
Chemical
Cimetidine
Famotidine
Ranitidine
Atrazine
Gabapentin
Meprobamate
Carbamazepine
Phenytoin
Alprazolam
Nordiazepam
Diazepam
Nicotine
Dextromethorphan
Omeprazole + Esomeprazole
Piperonyl butoxide
Temazepam
Fluticasone
Caffeine
Amphetamine
Pseudoephedrine + Ephedrine
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Class
H2 Antagonists
H2 Antagonists
H2 Antagonists
Herbicide
Neurochemical Modulation
Neurochemical Modulation
Neurochemical Modulation
Neurochemical Modulation
Neurochemical Modulation
Neurochemical Modulation
Neurochemical Modulation
OTC
OTC
OTC
Pesticide
Sedative
Steroid
Stimulant
Stimulant
Stimulant

Table A3. Total concentrations (μg/L) of detected chemicals by class at the effluent site in January
and May 2018.
Total concentrations at the effluent site (μg/L)

Class
Antidepressant
Antihistamines
Degradate
Diabetes care
Analgesic, Anti inflammatory
Neurochemical Modulation
Antibiotic
Beta blocker
Corrosion inhibitor
H2 Antagonists
Antiviral
OTC
Antifungal
Cardiovascular Care
Stimulant
Sedative
Anti-malarial
Pesticide
Asthma Relief
Herbicide
Steroid

January
3.193
2.31013
2.0855
1.49
1.38575
1.23741
0.9924
0.98
0.713
0.3529
0.3268
0.23546
0.2072
0.1467
0.0965
0.0454
0.0302
0.0118
0.0109
0
0

May
4.15165
3.38293
1.58053
1.6
1.14895
1.10477
0.3907
0.701
0.267
0.9173
0.84117
0.117
0.2513
0.23843
0.0575
0.0423
0.0207
0.00844
0.00997
0.0118
0.00032
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Table B.1. Bioactivity data from the ToxCast database was used for alternative formulations of
chemicals detected in the analytical chemistry dataset as shown below.
Analytical chemistry dataset
Chemical Name

CASRN

ToxCast Database
Chemical Name

Amitriptyline
Bupropion
Chlorpheniramine
Clonidine
Codeine
Dextromethorphan
Diphenhydramine
Duloxetine
Pseudoephedrine + Ephedrine
Erythromycin
Citalopram
Fadrozole
Fexofenadine
Fluoxetine
Hydrocodone
Hydroxyzine
Propoxyphene
Metformin
Methadone
Morphine
Oseltamivir
Phenazopyridine
Promethazine
Propranolol
Quinine
Ractopamine
Raloxifene
Sertraline
Tamoxifen
Tiotropium
Tramadol
Valacyclovir
Venlafaxine
Verapamil

50-48-6
34911-55-2
132-22-9
4205-90-7
76-57-3
125-71-3
147-24-0
116539-59-4
299-42-3
114-07-8
59729-33-8
102676-47-1
83799-24-0
54910-89-3
125-29-1
68-88-2
469-62-5
657-24-9
76-99-3
57-27-2
196618-13-0
94-78-0
60-87-7
525-66-6
130-95-0
97825-25-7
84449-90-1
79617-96-2
10540-29-1
186691-13-4
27203-92-5
124832-26-4
93413-69-5
52-53-9

Amitriptyline hydrochloride
Bupropion hydrochloride
Chlorpheniramine maleate
Clonidine hydrochloride
Codeine hydrochloride
Dextromethorphan hydrobromide monohydrate
Diphenhydramine hydrochloride
Duloxetine hydrochloride
Ephedrine hydrochloride
Erythromycin estolate
Escitalopram oxalate
Fadrozole hydrochloride
Fexofenadine hydrochloride
Fluoxetine hydrochloride
Hydrocodone phosphate (2:3) monohydrate
Hydroxyzine hydrochloride
Levopropoxyphene napsylate
Metformin hydrochloride
Methadone hydrochloride
Morphine sulfate pentahydrate
Oseltamivir tartrate
Phenazopyridine hydrochloride
Promethazine hydrochloride
Propranolol hydrochloride
Quinine hydrochloride dihydrate
Ractopamine hydrochloride
Raloxifene hydrochloride
Sertraline hydrochloride
Tamoxifen citrate
Tiotropium bromide
Tramadol hydrochloride
Valacyclovir hydrochloride
Venlafaxine hydrochloride
Verapamil hydrochloride
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CASRN
549-18-8
31677-93-7
113-92-8
4205-91-8
1422-07-7
6700-34-1
147-24-0
136434-34-9
50-98-6
3521-62-8
219861-08-2
102676-31-3
153439-40-8
56296-78-7
NOCAS_47802
1244-76-4
5714-90-9
1115-70-4
1095-90-5
6211-15-0
NOCAS_45954
136-40-3
58-33-3
318-98-9
6119-47-7
90274-24-1
82640-04-8
79559-97-0
54965-24-1
136310-93-5
36282-47-0
124832-27-5
99300-78-4
152-11-4

Table B.2 Chemical-assay combinations excluded from consideration in generation of EAR
values. *indicates assays that were removed from consideration across all chemicals.
CAS

31677-93-7
31677-93-7
31677-93-7
78-44-4
76824-35-6
153439-40-8
60142-96-3
60142-96-3
532-03-6
532-03-6
54-11-5
54-11-5
73590-58-6
73590-58-6
73590-58-6
66357-35-5
66357-35-5
723-46-6
148-79-8
29385-43-1
29385-43-1
29385-43-1
66357-35-5
66357-35-5
66357-35-5
66357-35-5
137-58-6
137-58-6
137-58-6
137-58-6
137-58-6
137-58-6
137-58-6
137-58-6
137-58-6
137-58-6
147-24-0
18559-94-9
318-98-9
147-24-0
532-03-6
532-03-6

Chemical

Endpoint

Bupropion hydrochloride
Bupropion hydrochloride
Bupropion hydrochloride
Carisoprodol
Famotidine
Fexofenadine hydrochloride
Gabapentin
Gabapentin
Methocarbamol
Methocarbamol
Nicotine
Nicotine
Omeprazole
Omeprazole
Omeprazole
Ranitidine
Ranitidine
Sulfamethoxazole
Thiabendazole
Tolyltriazole
Tolyltriazole
Tolyltriazole
Ranitidine
Ranitidine
Ranitidine
Ranitidine
Lidocaine
Lidocaine
Lidocaine
Lidocaine
Lidocaine
Lidocaine
Lidocaine
Lidocaine
Lidocaine
Lidocaine
Diphenhydramine hydrochloride
Albuterol
Propranolol hydrochloride
Diphenhydramine hydrochloride
Methocarbamol
Methocarbamol

Tanguay_ZF_120hpf_ActivityScore*
TOX21_TSHR_wt_ratio*
TOX21_RT_HEPG2_FLO_40hr_ctrl_viability
TOX21_RT_HEPG2_FLO_24hr_viability
TOX21_RT_HEPG2_FLO_00hr_ctrl_viability
TOX21_RT_HEK293_GLO_40hr_viability
TOX21_RT_HEK293_FLO_40hr_viability
TOX21_RT_HEPG2_FLO_00hr_ctrl_viability
TOX21_RT_HEPG2_FLO_08hr_viability
TOX21_RT_HEPG2_FLO_16hr_ctrl_viability
TOX21_RT_HEK293_FLO_24hr_viability
TOX21_RT_HEK293_FLO_08hr_viability
TOX21_RT_HEK293_FLO_16hr_viability
TOX21_RT_HEK293_FLO_24hr_viability
TOX21_ERb_BLA_Antagonist_viability
TOX21_PR_BLA_Antagonist_viability
TOX21_PR_BLA_Agonist_viability
TOX21_RT_HEK293_FLO_08hr_viability
TOX21_RT_HEK293_FLO_40hr_viability
TOX21_RT_HEK293_GLO_16hr_viability
NHEERL_MHC_MHCvCellCount_dn
TOX21_RT_HEK293_FLO_32hr_viability
TOX21_RT_HEK293_FLO_24hr_viability
TOX21_RT_HEK293_FLO_16hr_viability
TOX21_RT_HEK293_FLO_00hr_viability
TOX21_RT_HEK293_FLO_16hr_viability
TOX21_RT_HEK293_FLO_24hr_viability
TOX21_RT_HEK293_FLO_32hr_viability
TOX21_RT_HEK293_GLO_08hr_viability
TOX21_RT_HEK293_GLO_16hr_viability
TOX21_RT_HEK293_GLO_24hr_viability
TOX21_RT_HEK293_GLO_32hr_viability
TOX21_RT_HEK293_GLO_40hr_viability
TOX21_RT_HEPG2_FLO_00hr_ctrl_viability
TOX21_RT_HEPG2_FLO_08hr_viability
TOX21_RT_HEPG2_FLO_16hr_ctrl_viability
TOX21_RT_HEPG2_FLO_24hr_viability
TOX21_RT_HEPG2_FLO_32hr_ctrl_viability
NVS_GPCR_hM3
TOX21_p53_BLA_p5_ratio
TOX21_RT_HEK293_FLO_08hr_viability
ACEA_AR_agonist_AUC_viability
TOX21_RT_HEPG2_FLO_40hr_ctrl_viability
TOX21_RT_HEK293_FLO_00hr_viability
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Table B.3. Chemical-endpoint combinations that generated an EAR>0.001 from at least one
sampling event over the seven months analyzed (January-August 2018, excluding March)
Chemical

Endpoints

Biological target

Gene target

Acetaminophen

NVS_NR_hPR,
BSK_LPS_CD40_down
TOX21_RT_HEK293_FLO_16hr_viability
NVS_GPCR_rOpiate_NonSelective
NVS_TR_rSERT
NVS_ADME_hCYP2C19
CLD_CYP1A2_48hr
NVS_ENZ_hPPP2CA
CLD_CYP1A1_48hr
CLD_CYP1A2_24hr
CLD_CYP1A1_24hr
TOX21_RT_HEPG2_FLO_16hr_ctrl_viability
TOX21_RT_HEPG2_FLO_32hr_ctrl_viability
TOX21_RT_HEPG2_FLO_40hr_ctrl_viability
NVS_GPCR_hM5
NVS_ADME_hCYP2D6
NVS_GPCR_p5HT2C
NVS_GPCR_hM1
NVS_TR_gDAT
NVS_GPCR_hM4
NVS_GPCR_gH2
NVS_GPCR_gMPeripheral_NonSelective
NVS_GPCR_hM2
NVS_GPCR_h5HT7
NVS_TR_hDAT
NVS_GPCR_bH1
NVS_GPCR_hH1
TOX21_DT40_657
TOX21_DT40
TOX21_DT40_100
TOX21_RT_HEK293_FLO_24hr_viability
TOX21_RT_HEK293_FLO_32hr_viability
TOX21_TSHR_Agonist_ratio
NVS_GPCR_hAdoRA2a
OT_AR_ARELUC_AG_1440
TOX21_RT_HEK293_FLO_08hr_viability
NVS_ENZ_rMAOAC
NVS_GPCR_hAdoRA1
TOX21_p53_BLA_p3_viability
TOX21_RT_HEPG2_GLO_24hr_ctrl_viability
TOX21_RT_HEPG2_FLO_08hr_viability
TOX21_GR_BLA_Agonist_ratio
TOX21_AR_LUC_MDAKB2_Agonist
OT_AR_ARELUC_AG_1440
NVS_ENZ_hPDE4A1
ACEA_AR_agonist_80hr
TOX21_RT_HEK293_FLO_40hr_viability
TOX21_RT_HEK293_FLO_00hr_viability
TOX21_RT_HEK293_FLO_08hr_viability
TOX21_RT_HEK293_FLO_24hr_viability
NVS_LGIC_rNNR_BungSens
NVS_LGIC_hNNR_NBungSens

Steroidal
Inflammatory Factor
Cytotoxicity
Rhodopsin-Like Receptor
Neurotransmitter Transporter
Xenobiotic Metabolism
Basic Helix-Loop-Helix Protein
Serine/Threonine Phosphatase
Basic Helix-Loop-Helix Protein
Basic Helix-Loop-Helix Protein
Basic Helix-Loop-Helix Protein
Cytotoxicity
Cytotoxicity
Cytotoxicity
Rhodopsin-Like Receptor
Xenobiotic Metabolism
Rhodopsin-Like Receptor
Rhodopsin-Like Receptor
Neurotransmitter Transporter
Rhodopsin-Like Receptor
Rhodopsin-Like Receptor
Rhodopsin-Like Receptor
Rhodopsin-Like Receptor
Rhodopsin-Like Receptor
Neurotransmitter Transporter
Rhodopsin-Like Receptor
Rhodopsin-Like Receptor
DNA Repair
DNA Repair
DNA Repair
Cytotoxicity
Cytotoxicity

PGR
CD40

Carisoprodol
Methadone
hydrochloride
Fluconazole
Thiabendazole

Chlorpheniramine
maleate
Diphenhydramine
hydrochloride

Acyclovir
Lamivudine
Albuterol
Theophylline
Tolyltriazole
17Dimethylxanthine
Cotinine
Metformin
hydrochloride
Ranitidine
Atrazine
Carbamazepine
Diazepam

Nicotine
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Rhodopsin-Like Receptor
Steroidal
Cytotoxicity
Monoamine Oxidase
Rhodopsin-Like Receptor
Cytotoxicity
Cytotoxicity
Cytotoxicity
Steroidal
Steroidal
Steroidal
Phosphodiesterase
Steroidal
Cytotoxicity
Cytotoxicity
Cytotoxicity
Cytotoxicity
Ligand-Gated Ion Channel
Ligand-Gated Ion Channel

OPRM1
SLC6A4
CYP2C19
CYP1A2
PPP2CA
CYP1A1
CYP1A2
CYP1A1

CHRM5
CYP2D6
HTR2C
CHRM1
SLC6A3
CHRM4
Hrh2
CHRM3
CHRM2
HTR7
SLC6A3
HRH1
HRH1

TSHR
ADORA2A
AR
Maoa
ADORA1

NR3C1
AR
AR
PDE4A
AR

Chrna7
CHRNA2

Chemical

Endpoints

Biological target

Omeprazole

TOX21_RT_HEK293_FLO_32hr_viability
TOX21_RT_HEK293_GLO_24hr_viability
TOX21_RT_HEK293_FLO_40hr_viability
TOX21_AP1_BLA_Agonist_ratio
NVS_ADME_hCYP3A4
NVS_ADME_hCYP2J2
TOX21_GR_BLA_Agonist_ratio
TOX21_AR_LUC_MDAKB2_Agonist_3uM_Nilutamide
TOX21_AR_LUC_MDAKB2_Agonist
NVS_GPCR_bAdoR_NonSelective
ATG_Sox_CIS_up
TOX21_RT_HEK293_FLO_32hr_viability
TOX21_RT_HEK293_FLO_24hr_viability
TOX21_ARE_BLA_agonist_ratio
NVS_GPCR_hAdoRA2a

Cytotoxicity
Cytotoxicity
Cytotoxicity
Basic Leucine Zipper
Xenobiotic Metabolism
Xenobiotic Metabolism
Steroidal
Steroidal
Steroidal
Rhodopsin-Like Receptor
HMG Box Protein
Cytotoxicity
Cytotoxicity
Basic Leucine Zipper
Rhodopsin-Like Receptor

Piperonyl
butoxide
Fluticasone
propionate
Caffeine

101

Gene target

FOS|JUN
CYP3A4
CYP2J2
NR3C1
AR
AR
ADORA1
SOX1
NFE2L2
ADORA2A
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Figure B.1. Chemical measurements in ng/L for the 113 pharmaceuticals and CECs detected in Muddy Creek January-August 2018.111

